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ABSTRACT 
Current influenza virus hemagglutinin (HA)-based vaccines leave a significant gap to 
improve the vaccine effectiveness against mismatched strains and for the elderly. The goal of my 
dissertation research projects was to develop influenza vaccination strategies for inducing more 
effective cross-protection in mouse animal models.  
In chapter one, I investigated whether enhanced cross-protection would be induced after 
vaccination with recombinant influenza H3N2 virus expressing extra conserved M2e epitopes in 
a chimeric HA molecule (rgH3N2 4xM2e).  Intranasal vaccination of BALB/c mice with live rgH3N2 
4xM2e virus induced humoral and cellular immune responses to M2e and conferred broad cross-
protection against the different subtypes of influenza viruses. These findings provide evidence 
that new recombinant virus vaccination can enhance the cross-protective efficacy by inducing 
immunity to HA and M2e. 
The concerns about negative impacts on the efficacy of repeated influenza vaccination 
have been raised. In the second chapter, I studied the impact of heterologous prime-boost 
vaccinations on cross-protection utilizing recombinant H1N1 and H3N2 subtype influenza viruses 
expressing chimeric HA (4xM2e-HA) in C57BL/6 mice known to be a lower responder than BALB/c 
mice. I demonstrated that heterologous prime-boost immunization with recombinant 4xM2e-HA 
viruses was more effective in inducing cross-protective M2e and HA stalk specific IgG antibodies 
and cross-protection than homologous prime-boost immunization. The research outcomes from 
project two support the positive impacts of a heterologous prime-boost strategy on conferring 
more effective cross-protection.  
In the last chapter, I determined whether influenza HA virus-like particle (HA VLP) 
vaccination would induce homologous and heterologous protection in aged (18-month-old) 
BALB/c mice, in comparison with young adult (6-8 weeks old) mice. I found that higher doses of 
HA VLP were required in aged mice to induce homologous and heterologous protection. Aged 
mice displayed a lower capacity to induce IgG antibodies cross-reactive to different viral antigens 
and HA stalk domains, suggesting limited diversity of de novo B cell repertoire. Notably, 
incorporation of cytokine molecular adjuvants onto HA VLP enhanced protective efficacies as 
evidenced by more effective lung viral controls in aged mice. These findings provide insights into 
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1.1 Influenza virus 
Influenza virus causes a contagious respiratory disease accompanied by moderate to 
severe symptoms that can lead to death. The CDC estimates 12,000 to 61,000 annual deaths since 
2010 in the U.S. Out of 4 genera of influenza (types A, B, C, and D), influenza A and influenza B 
are clinically related in human disease and cause seasonal influenza epidemics annually. Influenza 
A has been evolving faster and more diverse than influenza B accompanied by changes in their 
amino acid and antigenic properties (Nobusawa and Sato, 2006). Influenza A belonging to the 
Orthomyxoviridae family possesses eight segmented genomes of negative-sense single-stranded 
RNA in the form of viral ribonucleoprotein particles (polymerase basic protein 2 (PB2), 
polymerase basic protein 1 (PB1), polymerase acidic protein (PA), hemagglutinin (HA), 
nucleoprotein (NP), neuraminidase (NA), matrix (M), and nonstructural (NS)). Influenza A viruses 
are subdivided into antigenically different subtypes based on the two major surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). 16 HAs and 9 NAs have been 
described to involve influenza A reassortment from a total of 18 HAs (H1-H18) and 11 NAs (N1-
N11) that include bat influenza A-like viruses (Krammer et al., 2018b). Influenza A is solely 
responsible for a pandemic that occurs due to the emergence of novel strains/subtypes of viruses 
with its broad variety of animal species reservoirs (Long et al., 2019). Prior history of pandemic 
records includes 1918 H1N1,1957 H2N2, 1968 H3N2, and 2009 H1N1 influenza A viruses 
(Taubenberger et al., 2019). The 1918 H1N1 pandemic caused an estimate of 50 million deaths 
worldwide, while the 1957 H2N2 pandemic and the 1968 H3N2 pandemic each reported 
approximately one million lives (Taubenberger et al., 2019). The most recent 2009 H1N1 
2 
pandemic claimed about 284,000 deaths (Nickol and Kindrachuk, 2019). The influenza A viruses 
can be divided into two groups based on the phylogenetic differences in HA proteins. H1, H2, H5, 
H6,  H8, H9, H11, H12, H13, H16, H17, and H18 belong to Group 1 and group 2 comprises H3, H4, 
H7, H10, H14, and H15 (Sutton et al., 2017).  
1.2 Influenza virus life cycle 
Influenza virus infects respiratory tracts and mainly replicates in epithelial cells. Virus 
infection starts with binding to the host epithelial cells in the upper respiratory tracts. HA plays a 
role for this attachment by recognizing sialic acid on the cellular surface with host specificity. HA 
proteins from human adapted influenza viruses bind preferentially to α-2,6 sialic acid (SA) that 
abundant in the human upper respiratory tract (URT) while the avian influenza viruses tend to 
bind to α-2,3 SA that found on epithelial cells of the human lower respiratory tract (LRT) and 
birds’ intestinal tract (Shao et al., 2017, Krammer et al., 2018b).  Viruses are then internalized 
into the cells by endocytosis. The conformational change of HA induced by acidification involves 
the fusion between the viral envelop and cellular membrane.  Released eight viral genetic 
materials: PB2, PB1, PA, HA, NP, NA, M, and NS in the cytoplasm are imported into the nucleus 
of the host cells for transcription and replication. The RNA polymerase complex composed of 
three subunits such as PB2, PB1, and PA is responsible for both transcription and replication. The 
8th RNA gene segment, NS encodes two proteins including NS1 and NS2, and RNA segment 7 (M) 
carrying to open reading frames encodes M1 and M2 proteins. Budding of new virions from the 
host plasma membrane is facilitated by NA that separates and release the viruses through SAs 
removal following the hydrolysis of the glycosidic linkage (Dou et al., 2018). 
3 
1.3 Targets for influenza vaccines 
Vaccine components are annually updated by WHO with the prediction of virus strains 
that would be circulated for the upcoming influenza season. However, the influenza vaccine 
effectiveness was estimated between 10% and 60% during 2004-2020 season (CDC, 2021e). 
Current hemagglutinin (HA)-based seasonal vaccines are suboptimal in providing cross-
protection against antigenically distinct influenza viruses due to the hypervariability of HA. If the 
vaccine strains mismatch with circulating viruses, the vaccine effectiveness can be dramatically 
reduced. The shortcoming of current influenza virus vaccines necessitates the development of 
more effective and universal vaccines such as by targeting highly conserved viral epitopes to 
confer cross-protection against newly emerging influenza viruses. 
1.3.1 Hemagglutinin (HA) 
Hemagglutinin (HA) is most abundant surface glycoprotein of influenza virus (Wu and 
Wilson, 2020) with 300-400 HA spikes. HA0 is a HA precursor and must be cleaved into HA1-HA1 
dimer form that is linked by single disulfide bonds for viral infection. The presence of a polybasic 
HA cleavage site is associated with high virulence. Immunodominant head domain located central 
part of HA1 is the primary target of the antibody response (inducing neutralizing antibodies) but 
antigenically highly variable. All antigenic sites are presented in the globular head domain in H1 
and H3 HAs. By contrast, immunosubdominant HA stalk found in HA2 is the highly conserved 
(Nachbagauer and Palese, 2020).  Antibodies specific to highly conserved HA stalk domain have 
been described to confer broad protection with neutralizing activity and antibody-dependent 
cell-mediated cytotoxicity (ADCC). To enhance the immunogenicity of the HA stalk domain, 
headless HA constructs have been generated (Impagliazzo et al., 2015, Yassine et al., 2015). Also, 
4 
a sequential chimeric HA (HAs carrying identical stalk domain but antigenically different HA 
subtype head domains) immunization strategy has been developed (Hai et al., 2012, Chen et al., 
2016). A phase I clinical study reporting the safety and ability of chimeric HA-based vaccines to 
induce cross-reactive anti-HA stalk domain antibodies suggested the potential as a universal 
vaccine development (Nachbagauer et al., 2021). Recently, a conserved protective determinant 
in the HA head domain from the interface of the HA trimer has been newly found. The antibodies 
to the conserved head domain showed inhibition of cell-to-cell virus spread (Bangaru et al., 
2019).  
1.3.2 Neuraminidase (NA) 
Neuraminidase (NA) is the second major glycoprotein (10- 20%) on the virion surface, with 
about 40-50 NA spikes (McAuley et al., 2019). NA is less variable and shows lower antigenic 
mutation rates compared to HA (Sandbulte et al., 2011). Antibodies to NA are mostly non-
neutralizing and have been known to inhibit virus budding from the host cells. Moreover, anti-
NA antibodies induce cross-protective immunity within a subtype and confer protection against 
lethal infection in animal models. In research performed with guinea pigs showed that NA-based 
vaccination prevented the transmission of the virus (McMahon et al., 2019). An independent role 
in the protection of antibodies to viral NA has been suggested (Monto et al., 2015, Walz et al., 
2018). Almost 100% conserved epitope in the NA (NAe, NA amino acids 222–230, located close 
to the enzymatic active site) was demonstrated in all influenza A subtypes and influenza B viruses 
(Stadlbauer et al., 2019, Gravel et al., 2010). This universally conserved NA epitope has been 
suggested as a potential cross-protective target for vaccine design. The current vaccines including 
inactivated virus and live attenuated virus vaccines, are poorly immunogenic to induce NA2e 
5 
specific antibodies. To enhance the immunogenicity of NAe, recombinant influenza virus carrying 
chimeric HA conjugates with NAe epitope was generated, and the contribution of NAe for cross-
protection was recently reported (Kim et al., 2020). 
 1.3.3 Matrix Protein 2 (M2) 
Matrix protein 2 (M2, 97 amino acids) found in influenza A virus is an integral 
transmembrane protein that consists of the N-terminal ectodomain (M2e, aa2-24), 
transmembrane (TM) domain (aa25-46), and amphiphilic C-terminal cytoplasmic tail (aa47-97) 
(Du et al., 2021). The M2 protein is a proton-selective ion channel responsible for internal 
acidification (by fluxing of H+ ions) of the influenza virus, which is crucial for viral entry and egress 
(Liang et al., 2016). The low pH of the endosome induces the HA-mediated membrane fusion. 
The extracellular domain M2e is evolutionary highly conserved, contains its eight N-terminal 
residues (aa2-9, SLLTEVET) which co-translated with matrix protein and thus exhibit more than 
99% similarity in all influenza A viruses (Liu et al., 2005). The antibodies specific for M2e were 
detected during virus infection (Nachbagauer and Palese, 2020) and M2e antibodies have been 
shown to be protective in animals including mice and ferrets (El Bakkouri et al., 2011, 
Mezhenskaya et al., 2021b, Wise et al., 2012). M2e-based immunity is infection permissive that 
does not neutralize the virus, while reducing the clinical symptoms. (Schotsaert et al., 2013). The 
mechanism of protection is known to rely on Fc-mediated antibody functions such as antibody-
dependent cellular cytotoxicity (ADCC), antibody-dependent phagocytosis (ADP) and antibody-
dependent complement activation (Vanderven and Kent, 2020). Also, T cell responses of M2e-
specific CD4+ and CD8+ have been found to contribute to protection (Wu et al., 2007, Eliasson et 
al., 2018). The M2 protein is abundantly expressed on the infected cell surface, however, natural 
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influenza virus infection induces a weak anti-M2e antibody response (Feng et al., 2006). A 
possible reason for this low immunogenicity can be the small size of M2e with its low number of 
copies incorporated into the virion compared to other large surface glycoproteins such as HA and 
NA (Hutchinson et al., 2014). Therefore, M2e based vaccines have been focusing on improving 
the reactivity of M2e, for example M2e presenting virus-like particles (VLPs), flagellin-linked M2e, 
or DNA or RNA vectors are used (Schepens et al., 2018). M2e-based vaccines are not available 
yet, but they have been undergoing extensive trials in preclinical animal models and also clinical 
trials (Mezhenskaya et al., 2019).  Although the induced antibodies specific for the conserved 
domains have been suggested to contribute to cross-protection, their protective efficacy tends 
to be weak. Antibodies against these conserved domains are relatively rare in humans because 
those epitopes are immunosubdominant. M2e- or NA-based vaccines induce non-neutralizing 
immunity that is less effective for protection compared to neutralizing immunity elicited by 
conventional HA globular head-based vaccines. Although HA stalk-based vaccine induces 
neutralizing antibodies, it is insufficient to confer strong protection possibly due to the poor 
accessibility of the antibodies to the HA stalk domain on the virus and inability to block the entry 
of virus infection. In contrast to the HA head specific antibodies, the antibodies against M2e, HA 
stalk, and NA do not inhibit the viral entry into the host cells and this might be able to provide a 
higher chance of allowing virus replication (Jang and Seong, 2014). 
1.4 Reverse genetics 
The nature of the influenza virus allowing the reassortment due it its segmented genomes 
has been utilized in the laboratory to generate reassortant viruses for their use as vaccines (either 
inactivated or live-attenuated influenza vaccines). The reverse genetics system using eight 
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plasmids (encoding influenza viral RNA segments) enabled to creation of recombinant influenza 
viruses (Neumann et al., 1999). The cold-adapted (ca) A/Ann Arbor/6/60 (USA/Canada, and 
Europe) and ca A/Leningrad/134/17/57 (in Russia, India, and China) have been approved as a 
master donor virus (MDV) for human usage.  
The PR8-based (A/PR/8/34) reverse genetics technique is widely used in the laboratory to 
generate reassorted virus strains. The mutations in polymerase genes (PB1 and PB2) have been 
known to be critical for attenuation of A/PR8 (He et al., 2013).  
1.5 Immune responses of intranasal vaccination versus intramuscular vaccination 
Route of vaccination can affect immune responses. While intramuscular (i.m.) vaccination 
mainly induces a systemic immune response, intranasal (i.n.) vaccination can elicit both mucosal 
(at the local/distal mucosal sites) and systemic immune responses. The muscle blood rapidly 
takes the intramuscularly administered vaccine antigens and travels to the draining lymphoid 
tissues of the body (Oberdan Leo, 2011). However, non-invasive intranasal vaccines spread into 
the body at a relatively slower rate. Conventionally, i.m. vaccination mainly induces the secretion 
of IgG and IgA antibodies into the systemic blood systems. Meanwhile, i.n. vaccination induces 
systemic IgG (at relatively low levels) and IgA antibodies at local mucosal sites where are 
considered as frontline immunity by protecting respiratory or mucosal pathogens at the initial 
infection sites. Mucosal-associated lymphoid tissue (MALT) is a specialized tissue for the mucosal 
immune system (Mohn et al., 2018). Mucosal IgA shows cross-reactivity against virus variants. In 
mucosal immunity, dimeric secretory IgA (sIgA) fulfills a crucial role as a significant 
immunoglobulin on mucosal surfaces, which confer local protection against bacterial and viral 
pathogens in the nasal mucosa. Polymeric sIgA is more effective than monomeric serum such as 
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IgA or IgG since it can transfer to the mucous actively by transcytosis, and it is protected against 
degradation by the secretory components. sIgA recognizes commensal microbes and inhibits 
their overgrowth. Also, sIgA binds to luminal microbes and toxins to protect them from attaching 
to mucosal epithelial cells (Corthesy, 2013). Mucosal IgG also plays essential role in neutralizing 
the pathogens or mediating opsonization. The most common route of vaccination for the 
influenza vaccine is i.m. with an inactivated influenza virus vaccine (IIV). After vaccine 
administration, antigens are picked up by antigen presenting cells (APCs), such as dendritic cells 
(DCs) and macrophages. APCs move towards lymph nodes draining the site of injection. Upon the 
antigen encountering, the adaptive immune system is initiated and effector cells, including CD4 
T cells, cytotoxic T cells and antibodies are generated. These effector cells circulate the 
bloodstream and back to the site of injection. Systemic IgG antibodies and local mucosal IgG 
antibodies diffused from systemic IgG play a critical role in protection after IIV application via an 
intramuscular route (Sridhar et al., 2015). Whereas licensed live-attenuated influenza virus 
vaccine (LAIV) administration via i.n. can induce cross-reactive mucosal IgA and CD8+ cytotoxic T 
lymphocytes (CTL) in addition to IgG. Once LAIV is delivered intranasally mimicking natural 
infection, antigens taken up by DCs are transferred to the tonsils/adenoids. At this location, 
activation and proliferation of T and B cells are initiated by CD4 T cells. Also, affinity maturation 
and isotype switching of antibodies are carried out. Activated T and B cells back to the site of 
vaccination or infection and then enter the circulation system. Plasma cells secret specific 
mucosal antibodies and local antigen specific antibodies spread into circulation. Antibody 
secreting cell response remains longer with LAIV than IIV, and this can be explained by the 
extended duration of stimulation with LAIV due to its local administration and virus replication 
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(higher antigen content) in the nasal mucosa (Mohn et al., 2018). Also, LAIV induces lung tissue-
resident memory T cells, which provides long-term protection. LAIV can induce innate immune 
responses more intensively by providing multiple pathogen-associated molecules including viral 
RNAs which can be detected by pathogen recognition receptors (PRRs) such as TLR7 and TLR8 
which are recognizing single-strand RNA. In children, LAIV induces higher immunogenic 
responses and better efficacy than IIV. LAIV elicits a T-cell response in children. Since pre-existing 
immunity in adults might inhibit virus replication of LAIV, immunologically naïve children allow 
better replication of LAIV and induce more protective immune responses. The status of pre-
existing immunity might influence the efficacy of influenza vaccination. 
1.6 Immunosenescence in the elderly 
Annually, influenza results in approximately 650,000 deaths globally and people 65 years 
and older are at overwhelmingly higher risk with occupying 70 – 85 percent of seasonal flu-
related deaths (CDC estimation in the United States) (CDC, 2021b). Annual vaccination is known 
to be the most effective strategy to reduce the risk of influenza in the elderly by decreasing the 
risk of influenza from 6% to 2.4% (Tanner et al., 2021). However, the vaccine effectiveness (VE) 
in over-65 years (17-53%) is disproportionately dropping compared to young adults (70-90%) 
(Goodwin et al., 2006). Conventional influenza vaccine is less immunogenic (only 30-40%) in the 
elderly, and this results in at least 20% of failure in elderly recipients to induce hemagglutination 
inhibition (HAI) antibodies (Keren et al., 1988) known to be correlated with protection (Dunning 
et al., 2016). The low overall effectiveness is believed mainly due to an altered immune response 
that is different from children and young adults who are the primary targets for designing 
influenza vaccine (Ciabattini et al., 2018). The age-associated deleterious changes in the immune 
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system including immunosenescence and inflammaging are responsible for low vaccine 
effectiveness (Tanner et al., 2021). Immunosenescence refers an age-related immunological 
dysfunction accompanied by gradual deterioration in innate and adaptive immune responses. 
For example, downregulation of primary lymphoid organs causes decreased production of B and 
T cells progenitors; reduction of phagocytosis and chemotaxis and increased production of pro-
inflammatory cytokines and dysfunctional memory cells (Ciabattini et al., 2018). Inflammaging is 
the state of chronic hyperinflammation. The constantly increased basal levels of inflammation 
interfere with detecting and generating truly protective inflammatory responses to pathogens. 
Therefore, inflammaging substantially contributes to increased susceptibility in the elderly to 
infection (Lambert et al., 2012).  
Recipients’ viral history of influenza infection and vaccination would be considered for 
the vaccine effectiveness in the elderly. This can be described by the concept of original antigenic 
sin (OAS) proposing that an individual’s immune response is imprinted by previously encountered 
influenza viral antigens (Ranjeva et al., 2019). OAS could be beneficial and harmful in immunity 
against influenza. The elderly showed a lower infection rate compared to young people during 
the 2009 pandemic (swine flu, A/H1N1). It is believed that previous exposure to H1N1 viruses 
that were circulated in the late 1970s in older people conferred the protection by inducing the 
cross-immunity to conserved antigens. However, the increased susceptibility of the elderly to 
influenza virus infection in the 2013-2014 H1N1 season was observed while the young population 
with immunity to nonmutated antigens displayed enhanced protection (Tanner et al., 2021). In 
research investigated the effect of repeated vaccination (RV) in ferrets (Music et al., 2019) after 
A/Hong Kong H3N2 challenge, the ferrets immunized once (current season only) showed lower 
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viral shedding, less body weight loss and relatively faster recovery of body weight compared to 
another group of ferrets repeatedly immunized with commercial vaccines twice (10 months 
apart). One explanation for reduced vaccine effectiveness in the RV group can be related to OAS. 
Suboptimal antibodies (to the conserved domains between two vaccines) for protection are 
amplified by repeated vaccination. 
To overcome the reduced vaccine effectiveness in the elderly, high-dose or adjuvanted 
vaccines have been developed to elicit more robust immunogenicity. 
1.7 Hypothesis and Research Objectives 
Chapter1: Broad cross-protection by recombinant live attenuated influenza H3N2 
seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin. 
The objective of project 1 was to determine whether intranasal immunization with live 
recombinant H3N2 virus expressing chimeric 4xM2e-HA would induce broadly cross-protective 
immunity against different subtypes of influenza A viruses in a mouse model. In recent years, 
antigenic drifts have severely limited the effectiveness of the H3N2 component of seasonal 
influenza vaccines. Here, using the reverse genetic (rg) technique, we generated reassortant 
seasonal influenza rgH3N2 4xM2e virus containing chimeric 4xM2e-HA in which the HA and NA 
genes were derived from A/Switzerland/9715293/2013 (H3N2) and the remaining 6 genes from 
the A/PR8 backbone. Reassortant rgH3N2 4xM2e virus containing chimeric 4xM2e-HA was found 
to retain comparable growth properties but displayed highly attenuated phenotypes in mice. 
Cross-protective efficacy against different subtypes (H1N1, H3N2, H5N1, H7N9, H9N2) of 
influenza A virus was tested in intranasally immunized BALB/c mice with rgH3N2 4xM2e. This 
12 
study implicates a strategy of improving cross-protection by utilizing currently licensed 
recombinant influenza vaccine platforms. 
Chapter2: Enhanced cross-protection by hetero prime-boost vaccination with 
recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes. 
The goal of project 2 was to test whether a strategy of hetero prime-boost vaccination 
with recombinant influenza viruses expressing chimeric 4xM2e-HA would induce more effective 
cross-protection than homologous prime-boost vaccination.  The impact of heterosubtypic 
vaccination with recombinant 4xM2e-HA influenza virus vaccines and pre-existing immunity on 
cross-protection against influenza viruses remains unknown. In this study, I investigated the 
efficacy of cross-protection by heterosubtypic prime- boost vaccination with live recombinant 
4xM2e-HA H1N1 and H3N2 influenza virus vaccines in C57BL/6 mice known to be a low responder 
to immune-subdominant conserved epitopes. The experimental outcomes of project 2 
demonstrated that hetero prime-boost strategies using recombinant 4xM2e-HA influenza virus 
vaccination induced more effective cross-protection against antigenically different viruses than 
homologous repeat vaccination in C57BL/6 mice. The roles of M2e and stalk immunity in 
conferring cross-protection were explored and discussed in this study. 
Chapter 3: Hemagglutinin virus-like particle is immunogenic and provides heterologous 
protection against influenza virus in young adult and aged mice. 
The goal of project 3 was to investigate immune responses and homo and cross-
protective efficacy in aged mice after vaccination with a platform of virus-like particles (VLP) 
presenting H1 HA with and without molecularly anchored cytokine adjuvants incorporated, in 
comparison with those in young adult mice. Vaccine effectiveness is inferior in the aged 
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population at high risk of severe illness from influenza virus infection. For the elderly, safe and 
highly immunogenic vaccines need to be developed. In project 3, host immune responses and 
homo and cross-protective efficacy was determined, after vaccination with a VLP vaccine 
platform which expresses H1 HA from A/PR8/34 (PR8 HA VLP) in young adults and aged (18-
month-old) BALB/c mice. In addition, I investigated the adjuvant impact of cytokines (GM-CSF 
and IL-12) engineered to be incorporated into HA VLP vaccines on inducing IgG antibodies, 
hemagglutination inhibition titers, and homo and hetero protection in aged mice, compared to 
those in young adult mice. Higher doses of vaccination with H1 HA VLP and cytokines 
incorporated onto H1 HA VLP were found to be more effective in inducing protective immunity 
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2.1 Abstract 
Hemagglutinin (HA)-based current vaccines provide suboptimum cross-protection. 
Influenza A virus contains an ion channel protein M2 conserved extracellular domain (M2e), a 
target for developing universal vaccines. Here we generated reassortant influenza virus rgH3N2 
4xM2e virus (HA and NA from A/Switzerland/2013/62/H3N2) expressing chimeric 4xM2e-HA 
fusion proteins with 4xM2e epitopes inserted into the H3 HA N-terminus. Recombinant rgH3N2 
4xM2e virus was found to retain equivalent growth kinetics as rgH3N2 in egg substrates. An 
intranasal single inoculation of mice with live rgH3N2 4xM2e virus was effective in priming the 
induction of M2e specific IgG antibody responses in mucosal and systemic sites as well as T cell 
responses. The rgH3N2 4xM2e primed mice were protected against a broad range of different 
influenza A virus subtypes including H1N1, H3N2, H5N1, H7N9, and H9N2. The findings support 
a new approach to improving current vaccine platforms’ efficacy by recombinant influenza virus 
inducing immunity to HA and cross-protective M2e antigens. 
2.2 Introduction 
Influenza virus causes one of the most common respiratory diseases in humans, resulting 
in significant public health concerns and deaths annually worldwide (Krammer et al., 2018b, 
Iuliano et al., 2018). Influenza A virus is a negative-sense single-stranded RNA virus containing 
eight segmented genomes, belonging to the Orthomyxoviridae family, and has an antigenic 
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variety from 18 subtypes (H1-H18) of hemagglutinin (HA) and 11 subtypes (N1-N11) of 
neuraminidase (NA) (Tong et al., 2013). Antigenic diversity is a challenging difficulty in preventing 
influenza. Vaccination has been the most effective preventive measure against influenza virus 
infection. The most common licensed platforms are inactivated influenza and live-attenuated 
influenza vaccines (LAIV). 
The overall vaccine effectiveness during the 2005-2018 seasons is a wide range of low 
efficacy between 10 and 60% as estimated in the US Flu Vaccine Effectiveness Network (CDC, 
2021e). Due to the emergence of drifting mutations in circulating H3N2 strains, the vaccine 
effectiveness against H3N2 was estimated to be 6% during the 2014–2015 season (Zimmerman 
et al., 2016, Shim et al., 2016). To overcome continued antigenic changes, universal vaccination 
strategies have been focused on inducing immunity to conserved epitopes and domains present 
in all influenza A viruses, including the M2 extracellular domain epitopes (M2e) (Saelens, 2019, 
Kolpe et al., 2017) and the HA stalk domains (Krammer and Palese, 2019, Nachbagauer et al., 
2015).  
Different platforms and vaccine adjuvants have been investigated to overcome the low 
immunogenicity of M2e epitopes. M2e-based vaccine candidates include Hepatitis B virus core 
protein conjugates (M2e-HBc) with adjuvants (Neirynck et al., 1999, De Filette et al., 2006), virus-
like particles (VLP) presenting M2e tandem repeats (5xM2e VLP) (Kim et al., 2013b), and flagellin 
conjugates (4.M2e-tFliC) (Wang et al., 2012) and fusion with oligomer stabilizing domains (M2e-
tGCN4) (De Filette et al., 2008). M2e expressing viral vectored vaccines were reported using 
adenovirus (Zhou et al., 2010), modified vaccinia virus Ankara (Hessel et al., 2014), and a T7-
bacteriophage (Hashemi et al., 2012).  These previous strategies inducing M2e immunity alone 
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were insufficient for conferring optimum protection and incompatible with current vaccine 
platforms. No universal vaccine against influenza is on the market. 
Vaccination of combined M2e VLP and inactivated influenza vaccines induced both cross-
protective M2e and strain specific HA immunity (Song et al., 2011, Kim et al., 2014). To enhance 
the cross-protective efficacy by a strategy of utilizing current vaccine platforms, recombinant 
influenza H1N1 virus A/Puerto Rico/8/1934 (A/PR8) was engineered to express chimeric 4xM2e-
HA where tandem M2e epitopes were inserted in the N-terminus HA (Kim et al., 2017a). A 
chimeric HA with a single M2e in the head site Ca was tested in inactivated recombinant A/PR8 
virus inducing cross-protection (Sun et al., 2019). However, the protection was not tested against 
a wide range of different subtypes.  
In recent years, antigenic drifts have severely limited the effectiveness of the H3N2 component 
of seasonal influenza vaccines. Here, using the reverse genetic (rg) technique, we generated 
reassortant seasonal influenza rgH3N2 4xM2e virus containing chimeric 4xM2e-HA in which the 
HA and NA genes were derived from A/Switzerland/2013/62 (H3N2) and the remaining 6 genes 
from the A/PR8 backbone. Reassortant rgH3N2 4xM2e virus containing chimeric 4xM2e-HA was 
found to retain comparable growth properties but display highly attenuated phenotypes in mice. 
An intranasal single inoculation of mice with rgH3N2 4xM2e virus could effectively induce a broad 
range of enhanced cross-protection against different influenza A virus subtypes including H1N1, 
H3N2, H5N1, H7N9, and H9N2. This study implicates a strategy of improving cross-protection by 
utilizing currently licensed recombinant influenza vaccine platforms. 
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2.3 Materials and Methods 
2.3.1 Cells and viruses 
For DNA transfection to generate reassortants, 293T cells obtained from ATCC were used 
and maintained in Dulbecco's Modified Eagle Medium media. Embryonated chicken eggs for 
influenza virus amplification were obtained from Hy-Line N.A. LLC (Mansfield, GA) and confirmed 
free of influenza virus. A/Puerto Rico/8/1934 (A/PR8, H1N1), A/Philippines/2/82 (A/Phil, H3N2), 
and rgH5N1 A/Vietnam virus which contains HA (polybasic residues removed) and NA from 
A/Vietnam/1203/2004 and six internal genes from A/PR8 were previously described (Song et al., 
2011). Reverse genetics (rg) H3N2 (А/Switzerland/2013, A/SW) is a reassortant virus X-247 with 
A/PR8 backbone (CDC influenza resources) containing HA and NA genes from A/Switzerland 
/9715293/2013 (H3N2) and 6 remaining genes from A/PR8. The viruses were inactivated using 
formalin (37%) at 1:4000 dilutions in purified virus concentrations (1 mg/ml) (Ko et al., 2018). The 
rgH7N9 is a reassortant virus containing HA and NA derived from A/Shanghai/2/2013 (H7N9) and 
the A/PR8 backbone genes (Deng et al., 2018). The reassortant H9N2 virus is A/chicken/Hong 
Kong/G9/1997 x PR8-IBCDC-2 (CDC influenza resources). The rgPR8 Ms, rgPR8 Mm and rgPR8 Mg 
reassortant viruses containing avian M2 were generated using the A/PR8 backbone genes by 
replacing an M gene from A/Shanghai/2/2013 (H7N9), A/Mandarin duck/Korea/PSC24-24/2010 
(H5N1) and A/Chicken/Korea/Gimje/2008 (H5N1) respectively. 
2.3.2 Generation of recombinant reassortant rgH3N2 virus containing 4xM2e-HA 
A full-length copy of the HA gene from А/SW (H3N2) was used to insert a cloning site for 
BsmBI restriction enzyme between the signal peptide (SP) sequence and N-terminus in the 
ectodomain of HA by polymerase chain reaction (PCR) primers. The two PCR products of SP 
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fragment and HA full-length with each BsmBI site were linked together by overlapping reactions 
of PCR products, resulting in the SP-BsmBI-HA construct with an H3 HA full length ectodomain 
and transmembrane domain. The 4xM2e encoding gene is composed of heterologous M2e 
sequences derived from human (2x hM2e), swine (1x sM2e), and avian (1x aM2e) influenza A 
viruses (Figure 1A) as described (Kim et al., 2017a). This 4xM2e gene was amplified using PCR 
primers with BsmBI sites for insertion into the SP-BsmBI-HA H3 construct in dual promoter pCI 
plasmid (Figure 1A). The inserted 4xM2e gene contains flexible linkers AAAGGAA or AAAPGAA 
between each M2e domain as well as between the 4xM2e sequence and the N-terminus H3 HA 
(Figure 1A). The correct insertion of 4xM2e into the full-length H3 HA was confirmed by DNA 
sequencing of the construct.  
To generate reassortant rgH3N2 virus containing 4xM2e-HA (rgH3N2 4xM2e), 293T cells 
were co-transfected with plasmids encoding 4xM2e-HA (H3) and N2 NA from А/SW (H3N2) and 
six other plasmids encoding the A/PR8 backbone genes. Two days after transfection, the 
supernatants were inoculated into 10-day-old embryonated chicken eggs. The rescue of 
replication-competent recombinant viruses was initially screened in allantoic egg fluids by a 
hemagglutination activity assay and the genetic identity of the reassortant vaccine virus was 
confirmed by sequence analysis.     
2.3.3 Characterization and pathogenicity of reassortant rgH3N2 4xM2e-HA virus 
The expression of 4xM2e-HA of the rescued reassortant viruses was characterized by 
enzyme-linked immunosorbent assay (ELISA) using influenza A virus M2e specific monoclonal 
antibody (14C2 mAb) (Abcam Inc., Cambridge, MA) or polyclonal antisera specific for the H3N2 
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virus. Growth capability and kinetics of rescued rgH3N2 4xM2e virus were compared with rgH3N2 
virus in embryonated eggs. 
To verify pathogenicity of recombinant rgH3N2 4xM2e virus compared to A/PR8 pathogenic WT 
virus, BALB/c mice were intranasally (IN) inoculated with 1x 105 or 1x 106 EID50 (50% egg 
infectious dose) of rgH3N2 4xM2e, rgH3N2, or 104 EID50 WT A/PR8 pathogenic viruses. At three 
days after IN infection, nasal turbinates and lung tissue samples were collected and homogenized 
in DMEM. The supernatants clarified by centrifugation were used to determine virus titers by 
limiting dilutions in the embryonated eggs and the limit of detection was 1.2 log10EID50/ml.  
Another set of mice (n=5 /group) infected with recombinant and WT viruses was monitored daily 
for 14 days to record body weight changes. 
2.3.4 Immunizations and virus challenge of mice 
BALB/c mice (n=30 /group, 6- to 8-week-old age, Jackson Laboratories) were IN inoculated 
with 105 EID50 for a prime single dose of recombinant rgH3N2 4xM2e or rgH3N2 virus. Another 
set of primed mice (n=15 /group) was boosted with 106 EID50 of recombinant rgH3N2 4xM2e or 
rgH3N2 virus at four weeks after priming. Blood samples were collected at two weeks after each 
inoculation for serological immune assays. After three weeks of prime or prime-boost dose 
inoculation, rgH3N2 4xM2e, rgH3N2 immune, or unvaccinated (mock) mice were challenged with 
different subtype viruses as indicated. LD50 dose causing 50% lethality in mice was pre-
determined. Differential challenge doses were used depending on the pathogenicity and subtype 
of virus and experimental conditions (prime, prime-boost, T cell depletion). All animal 
experiments in this study were approved by the Georgia State University IACUC review boards.  
Mouse animal experiments including virus infection, blood and tissue collections were performed 
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in accordance with the approved IACUC protocol (A21004) and regulations.  The study was 
carried out in compliance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
guidelines. 
2.3.5 Antibody ELISA and hemagglutination inhibition (HAI) assays 
Virus-specific antibody responses were determined by ELISA using inactivated H1N1 
(A/PR8), H3N2 (A/SW, A/Phil), or rgH5N1 viruses as a coating antigen (4µg/ml). M2e-specific 
antibody responses were determined using human, swine, and avian M2e peptide antigens of 
chemically synthesized 23 amino acids (aa) polypeptides as described (Kim et al., 2013b, Kim et 
al., 2014). IgG isotypes and IgA antibodies were measured using horse-radish peroxidase-
conjugated goat anti-mouse IgG1, IgG2a, and IgA secondary antibodies (Southern 
Biotechnology), color reactions developed with tetramethylbenzidine substrates (TMB, 
Invitrogen). Antibody levels are presented as optical density absorbance values at 450nm (BioTek 
ELISA plate reader) or concentrations as calculated using standard IgG and IgA (Southern 
Biotech).  Bronchoalveolar lavage fluids (BALFs) were obtained by infusing 1.5 ml of phosphate-
buffered saline (PBS) into the lungs (Kim et al., 2013b). HAI assays were determined against 
homologous, heterologous, and heterosubtypic influenza viruses using chicken red blood cells 
(Quan et al., 2009, Kim et al., 2014). Briefly, 1:4 ratios of sera and receptor destroying enzymes 
(RDE, Sigma) were mixed and incubated for 18 hours at 37°C. After inactivation, the RDE-treated 
sera were serially diluted and mixed with a virus (8 HA units). HAI titers were determined as the 
highest dilution factor inhibiting the formation of buttons with 0.5% chicken red blood cells. 
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2.3.6 In Vivo T-Cell depletion 
For in vivo systemic T-cell depletion prior to challenge, primed mice with rgH3N2 4xM2e 
or rgH3N2 received treatment with anti-CD4 (CD4 clone GK1.5) and/or anti-CD8 (CD8 clone 
53.6.7) mAbs. Antibodies (BioXCell, West Lebanon, NH) were injected into the mice with 
intraperitoneal (IP) and IN sequential delivery at two days interval (anti-CD4 200µg /mouse (IP) 
and 10 µg/mouse (IN), anti-CD8, 150 µg /mouse (IP), 10 µg/mouse (IN)). The levels of CD4 and 
CD8 T cells were below the detection after treating with CD4 and CD8 depleting antibodies as 
confirmed by flow cytometry of blood (Figure 12). All groups (n=4) were challenged with a lethal 
dose of A/PR8 H1N1 (1.5 LD50), rgPR8 Mg (3 LD50), rgPR8 Ms (10 LD50) or A/Phil H3N2 (17 LD50) 
influenza virus. Mice were monitored daily to record weight changes and mortality. 
2.3.7 Intracellular cytokine staining of T cells 
BALF and lung cells were stimulated with M2e peptides (SLLTEVETPIRNEWGSRSN) (5 
μg/mL) for 5 h at 37 °C in the presence of brefeldin A (BFA) (20 μg/mL). After stimulation, 
lymphocytes were stained with T cell marker mAb for CD4 (CD4-PE/Cy5, BD Biosciences) and CD8 
(CD8α-PE, Biolegend) by following a procedure of BD Cytofix/Cytoperm Plus Kit. Intracellular 
staining of the permeabilized lymphocytes was conducted with IFN-γ cytokine mAb (anti-mouse 
IFN-γ-APC/Cy7, BD Biosciences). All samples were analyzed using LSR-II/Fortessa flow cytometer 
(BD Biosciences, San Diego, CA, USA) and analyzed using the FlowJo software (FlowJo V10, Tree 
Star, Inc.). 
2.3.8 In vivo efficacy tests of immune sera 
Immune sera collected at 4 weeks after boost inoculation were heat-inactivated at 56°C 
for 30 min, 4 folds diluted, and then mixed with 2 LD50 of influenza virus rgH5N1 (A/Vietnam) and 
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incubated at room temperature for 1 hour as previously described (Kim et al., 2014, Song et al., 
2011). The rgH5N1 virus mixed with immune sera was used to IN infect naive mice (n = 3) and 
body weight and survival rates were daily monitored for 8 days.  
2.3.9 In vitro IgG antibody detection and cytokine ELISA assays 
Secreted IgG antibodies specific for M2e, rgH3N2 and A/Phil were determined from 
mediastinal lymph nodes (MLN) from BALB/c mice. The cells from MLN were isolated at day 6 
after challenge and cultured for 6 days in the plate pre-coated with M2e, rgH3N2 or A/Phil. The 
combined levels of IgG antibodies secreted into the culture supernatants and captured on the 
plate were analyzed by ELISA and presented. The inflammatory cytokines such as TNF-α, IFN-γ 
and IL-6 from bronchoalveolar lavage fluids (BALF) and lung extracts were measured by cytokine 
ELISA as described in the previous study (Lee et al., 2016b). Cytokines were detected using Ready-
SET-Go kits with TNF-α, IFN-γ or IL-6 specific antibodies (eBioscience, San Diego, CA). 
2.3.10 Statistical analysis 
Two-way or one-way ANOVA were used to determine the statistical significance when 
comparing two different conditions. P-values of less than or equal to 0.05 were considered 
significant. Data analysis was performed using Prism software (GraphPad Software Inc., San 
Diego, CA). 
2.4 Results 
2.4.1 Generation of reassortant influenza H3N2 virus vaccine containing 4xM2e in an 
HA conjugate 
The current strain specific HA-based influenza vaccine is less effective in conferring cross-
protection. M2e has been targeted to induce broad but weak cross-protection. To induce 
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immunity against both HA and highly conserved M2e epitopes, a seasonal A/Switzerland/2013 
H3 HA gene conjugated with four tandem M2e (4xM2e) repeat was constructed (Figure 1A and 
Table 1). Rescued viruses expressing wild type (WT) HA (rgH3N2) or chimeric HA (rgH3N2 4xM2e) 
were amplified in eggs and harvested. Antigenic characterization by ELISA showed that rgH3N2 
4xM2e virus was highly reactive to M2e specific mAb 14C2 whereas rgH3N2 and A/PR8 virus 
controls did not show such M2e reactivity (Figure 1B). Both rgH3N2 and rgH3N2 4xM2e viruses 
displayed high antigenic reactivity to mouse antisera of rgH3N2 infection and goat antisera of 
A/Indiana/2011 (H3N2) immunization (Figure 2). These results support that 6:2 reassortant 
rgH3N2 4xM2e virus displays high reactivity to M2e specific 14C2 mAb and retains similar 
antigenicity to antisera of H3N2 viruses as compared to rgH3N2 virus. 
 
Figure 1 Reassortants rgH3N2 and rgH3N2 4xM2e virus expressing chimeric 4xM2e-HA 
are attenuated in vivo 
(A) Diagram for chimeric 4xM2e-HA (H3) structures. The sequence H3 HA was derived from 
A/Switzerland/2013 (H3N2). SP: signal peptide, tandem repeat 4xM2e is composed of human, swine, and 
avian influenza A viruses. hM2e: SLLTEVETPIRNEWGSRSNDSSD, sM2e: SLLTEVETPTRSEWESRSSDSSD, 
aM2e: SLLTEVETPTRNEWESRSSDSSD.  L and C represent linker (AAAGGAA) and connector (AAAPGAA) 
respectively. (B) 14C2 M2e specific mAb ELISA assays were performed to characterize 6:2 reassortants 
rgH3N2 and rgH3N2 4xM2e viruses (4 µg/ ELISA plate well) generated by reverse genetics (rg) using the 
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A/PR8 backbone. (C) Infectious virus titers (EID50) of rgH3N2 and rgH3N2 4xM2e virus preparations in egg 
substrates. (D) Hemagglutination activity units (HAU, log2/50 µl) for rgH3N2 and rgH3N2 4xM2e viruses 
using chicken red blood cells. (E) Growth kinetics of reassortant viruses in embryonated chicken eggs at 
33°C infected with 104 EID50 of rgH3N2 and rgH3N2 4xM2e. c-e: A representative out of 2 repeats. (F) Body 
weight changes in BALB/c mice (n=10, too small variations to be shown) IN inoculated with reassortant 
rgH3N2 viruses (105-106 EID50) or A/PR8 (104 EID50). (G) Infectious virus titers (EID50) in nasal turbinates 
and lung extracts from mice (n=3, pooled) at 3-day post infection with A/PR8 (104 EID50), rgH3N2 (106 
EID50) and rgH3N2 4xM2e (106 EID50). 
 
 




Figure 2 ELISA assays to characterize 6:2 reassortants rgH3N2 and rgH3N2 4xM2e 
viruses generated by reverse genetics (rg) using the A/PR8 backbone  
(A) ELISA (4 µg/ ELISA plate well) using anti-rgH3N2 (A/Switzerland/9715293/2013 (H3N2)) mouse sera as 
primary antibody. (B) ELISA using anti-A/Indiana/2011 (H3N2) goat sera as primary antibody. 
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2.4.2 Reassortant rgH3N2 4xM2e virus is attenuated in mice but does not compromise 
replication capacity in egg substrates 
We determined whether rgH3N2 4xM2e virus would retain the comparable replication 
capacity in egg substrates, compared to WT rgH3N2.  Both chimeric rgH3N2 4xM2e and WT 
rgH3N2 viruses displayed similarly high levels of egg infectious titers (EID50/ml) and 
hemagglutination activity units (HAU) (Figure 1C, D). Next, at designated time points after 
incubation of embryonated chicken eggs with 104 EID50 of rgH3N2 or rgH3N2 4xM2e, in vitro 
growth kinetics of infectious titers (EID50) were determined (Figure 1E). The results showed that 
rgH3N2 4xM2e virus exhibited approximately equivalent growth kinetics in egg substrates as WT 
rgH3N2 virus. The reassortant rgH3N2 4xM2e virus does not compromise replication capacity in 
egg substrates. Consistent, the overall trends in the growth patterns of rgH3N2 and rgH3N2 
4xM2e reassortants in MDCK cells were similarly observed as those in the eggs despite some 
variations at different culture times and temperatures (Figure 3). Therefore, rgH3N2 4xM2e virus 
does not compromise replication capacity in egg substrates.  
As an indicator of pathogenicity, weight changes and activity were monitored in mice 
after intranasal inoculation with rgH3N2 4xM2e and rgH3N2 viruses. Both mouse groups infected 
with rgH3N2 (105 EID50) and rgH3N2 4xM2e (105 and 106 EID50) did not show body weight loss 
(Figure 1F) while the mice with A/PR8 even at a 100-fold lower dose (104 EID50) consistently 
displayed severe weight loss and died of infection. Consistent, mice inoculated with WT A/PR8 
virus showed highest levels of replicating viral titers in the lower respiratory tracts of lungs, which 
is at approximately 100 folds higher than those in the upper respiratory nasal turbinates at day 3 
post inoculation (104 EID50) (Figure 1G). In contrast, rgH3N2 (106 EID50) and rgH3N2 4xM2e (106 
26 
EID50) viruses showed approximately 105 magnitudes lower lung viral titers than WT A/PR8 virus 
(Figure 1G). Instead, 100 folds higher viral replications were observed in the nasal turbinates than 
those in the lungs after inoculation of mice with rgH3N2 and rgH3N2 4xM2e virus (Figure 1G). 
These results suggest that reassortant rgH3N2 and chimeric rgH3N2 4xM2e viruses are highly 
attenuated in mice with restricted replication in the upper respiratory tracts but retains 
replication capacity in egg substrates. 
 
Figure 3 . Growth kinetics for rgH3N2 and rgH3N2 4xM2e in MDCK cells 
Virus replications of rgH3N2 and rgH3N2 4xM2e were determined in MDCK cells at different time points 
at 33oC and 37oC culture temperature as indicated after inoculation. The titers were determined and 
presented in TCID50/ml (A) at 33°C and (B) at 37°C.  
 
2.4.3 Prime dose of live rgH3N2 4xM2e virus induces M2e specific IgG isotype antibody 
responses 
Intranasal prime inoculation of mice with live rgH3N2 4xM2e virus (105 EID50) induced 
M2e specific IgG1 and IgG2a antibody responses at significantly higher levels than rgH3N2 (Figure 
4A, B). IgG antibodies specific for human M2e were induced at higher levels in prime sera from 
rgH3N2 4xM2e vaccination than those specific for avian M2e or swine M2e (Figure 5A), 
suggesting possible contribution of the extra 2x hM2e in the rgH3N2 4xM2e construct. Both 
rgH3N2 and rgH3N2 4xM2e immunized groups showed similarly high levels of IgG isotype 
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antibodies specific for H3N2 virus (Figure 4C, D).  Both sera from rgH3N2 and rgH3N2 4xM2e 
immune mice exhibited vaccine strain specific HAI activities against rgH3N2 (A/Switzerland) virus 
(Figure 4E) but not against A/PR8 (H1N1), A/Philippines (A/Phil H3N2) and A/Vietnam (A/Viet 
rgH5N1). Therefore, prime dose of live rgH3N2 4xM2e but not rgH3N2 virus could induce M2e 
specific IgG isotype antibodies in mice. 
 
Figure 4 Intranasal prime inoculation of live rgH3N2 4xM2e virus induces M2e specific 
serum IgG isotype antibody responses  
(A) M2e specific IgG1 antibodies. (B) M2e specific IgG2a antibodies. (C, D) Virus rgH3N2 specific IgG1 and 
IgG2a antibodies. Serum samples were collected at 2 weeks after prime dose intranasal inoculation of 
mice (n=15 /group). (E) Serum HAI titers against the viruses (A/PR8, A/Phil, rgH3N2 and A/Viet) were 
determined 14 days after immunization. rgH3N2: 6:2 reassortant with WT HA and NA of 
A/Switzerland/2013. rgH3N2 4xM2e: 6:2 reassortant with 4XM2e-HA and NA of A/Switzerland/2013. Each 




Figure 5 IgG antibody responses to humanM2e, swine M2e, and avian M2e peptides 
after prime or prime boost vaccination with rgH3N2 4xM2e  
Mouse sera were collected 2 weeks after intranasal prime or prime boost inoculation of rgH3N2 
4xM2e. Total IgG antibody specific for human M2e (hM2e), avian M2e (aM2e) and swine M2e 
(sM2e) were measured from (a) prime and (b) boost sera. Error bars show mean ± SEM. The 
statistical significances between hM2e detection versus sM2e and aM2e were determined using 
two-way ANOVA and indicated in **, P < 0.01; ***, P < 0.001. 
 
2.4.4 Prime dose of live rgH3N2 4xM2e vaccination provides broad cross-protection 
Intranasally prime vaccinated mice with 105 EID50 of rgH3N2 or rgH3N2 4xM2e were 
challenged with different subtype influenza viruses including H1N1 (A/PR8), rgPR8 with avian M2 
(rgPR8 Mm, rgPR8 Mg), H3N2 (A/Phil), rgH5N1 (A/Viet), rgH7N9 (A/Shanghai), and rgH9N2 
(A/Hong Kong). The rgH3N2 4xM2e group showed higher survival rates (100%) and a trend of less 
weight loss against A/PR8 challenge, compared to the rgH3N2 group with 60% survival rates (Figs. 
6A, E). Next, we tested PR8 reassortants containing avian M2 (rgPR8 Mm, rgPR8 Mg, Figs. 7A, B, 
D, E) as a challenge virus, following single-dose vaccination with rgH3N2 or rgH3N2 4xM2e. The 
rgH3N2 4xM2e group tends to show less weight loss against rgPR8 Mm (M gene from A/Mandarin 
duck/Korea/PSC24-24/2010, H5N1) or rgPR8 Mg (M gene from A/Chicken/Korea/Gimje/2008, 
H5N1), compared to those in the rgH3N2 control group. When challenged with a wild type 2009 
H1N1 pandemic A/California/04/09 virus containing swine M2, similar trend was observed. The 
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rgH3N2 4xM2e primed mice showed a pattern of less weight loss and quicker recovery than the 
rgH3N2 group (Figure 8). However, the difference between these two groups was not statistically 
significant.  
To test the breadth of cross-protection, different subtypes of PR8 reassortants were used 
as a challenge virus. The rgH3N2 4xM2e primed mice exhibited significantly less weight loss (~5%) 
than rgH3N2 primed mice (~16%) at day 5 after challenge with rgH5N1 (Figs. 6B, F). Similarly, 
when challenged with rgH7N9 virus, the rgH3N2 4xM2e group displayed average weight loss 6% 
compared to 19% weight loss in rgH3N2 prime mice and the mock control with over 20% weight 
loss and 0% survival rates (Figs. 6C, G). After a high lethal dose (100 LD50) challenge with rgH9N2 
virus, rgH3N2 4xM2e primed mice showed 75% survival protection whereas rgH3N2 immune and 
mock control mice all died of infection (Figs. 7C, F). When challenged with rgH9N2 at 20 LD50 
dose, rgH3N2 4xM2e primed mice showed better protection as evidenced by significantly 
preventing weight loss (average 11% day 6) and enhancing survival rates than rgH3N2 immune 
mice displaying 25% weight loss (day 6) and 25% survival rates (Figs. 6D, H).  
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Figure 6 A single dose of live rgH3N2 4xM2e virus provides enhanced heterosubtypic 
cross-protection against different subtype influenza A viruses  
Weight changes and survival rates in primed mice after challenge with (A, E) H1N1 A/PR8 (3 LD50), (B, F) 
rgH5N1 A/Vietnam (5 LD50), (C, G) rgH7N9 virus (reassortant A/Shanghai, 6 LD50) and (D, H) rgH9N2 virus 
(reassortant A/Hong Kong, 20 LD50). Differential challenge doses were used depending on the 
pathogenicity and HA phylogenic distance of virus. Groups of mice (n=5 or 6) were intranasally primed 
with rgH3N2 (105 EID50) or rgH3N2 4xM2e (105 EID50) and then challenged 3 weeks later. Two 
independent repeat of mouse challenge experiments confirms the reproducibility of data.  rgH3N2: 6:2 
reassortant with WT HA and NA of A/Switzerland/2013. rgH3N2 4xM2e: 6:2 reassortant with 4XM2e-HA 
and NA of A/Switzerland/2013. Each individual mouse animal is analyzed.  Error bars show mean ± SEM. 
The statistical significances between rgH3N2 group versus rgH3N2 4xM2e group were determined using 




Figure 7 A single dose of live rgH3N2 4xM2e virus provides enhanced heterosubtypic 
cross-protection against A/PR8 (H1N1) reassortants containing avian M gene or rgH9N2 virus 
 (A-C) Weight changes and (D-F) survival rates after challenge with rgPR8 Mm (M gene from A/Mandarin 
duck/Korea/PSC24-242010, H5N1, 1 LD50), rgPR8 Mg (M gene from A/Chicken/Korea/Gimje/2008, H5N1, 
3 LD50) and high dose of rgH9N2 virus (reassortant A/Hong Kong, 100 LD50), respectively. Groups of mice 
(n=3 or 4) were intranasally primed with rgH3N2 (105 EID50) or rgH3N2 4xM2e (105 EID50) and then 
challenged 3 weeks later. Error bars show mean ± SEM. The statistical significances between rgH3N2 
group versus rgH3N2 4xM2e group were determined using two-way ANOVA and indicated in *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. 
 
 
Figure 8 Body weight changes in BALB/c mice after challenge with A/California virus 
containing swine M2 
The groups of BALB/c mice were infected with A/California/04/09 (6 LD50) containing swine M2 at 3 weeks 
after single dose intranasal immunization with rgH3N2 or rgH3N2 4xM2e (105 EID50 each). 
A/California H1N1

























Figure 9 Prime dose rgH3N2 4xM2e provides enhanced protection against 
heterologous H3N2 A/Phil virus and M2e specific IgG and IgA antibodies in mucosal sites 
The mice primed with rgH3N2 or rgH3N2 4xM2e were challenged with heterologous A/Phil H3N2 
virus (50 LD50). A relatively high challenge dose was used because of the same subtype virus. (A) Body 
weight changes after A/Phil challenge. Two independent repeat of mouse challenge experiments confirms 
the reproducibility of data. (B) Lung viral titers (TCID50 x100/ml) at 5-day post challenge with A/Phil. (C-F) 
IgG and IgA antibody responses specific for M2e or viral (rgH3N2, A/Phil) antigens in BALF and lung 
extracts at 5 days after challenge. ELISA viral antigens are rgH3N2 and A/Phil. Error bars indicate mean 
value ± SEM. The statistical significances between rgH3N2 group versus rgH3N2 4xM2e group were 
determined using two-way ANOVA (a, c-e) or one-way ANOVA (b) and indicated in *, P < 0.05; **, P < 0.01; 
***, P < 0.001. 
 
After challenge with A/Phil (H3N2), 3% weight loss was observed with rgH3N2 4xM2e 
primed mice in contrast to 12% weight loss was observed with rgH3N2 primed mice (Figure 9A). 
Collectively, these results suggest that single dose intranasal priming of mice with rgH3N2 4xM2e 
could provide enhanced cross-protection against diverse subtypes of influenza A viruses 
containing human or avian M2. 
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2.4.5 Priming with rgH3N2 4xM2e virus results in enhanced responses of M2e specific 
IgG and IgA antibodies in mucosal respiratory and systemic sites upon challenge 
Consistently, the mice that received a single dose (105 EID50) of rgH3N2 4xM2e showed 
more effective cross-protection against A/Phil H3N2 virus as evidenced by less weight loss 
compared to the mice with rgH3N2 (Figure 9A). At day 5 post infection with A/Phil, naive mice 
showed the highest levels of lung virus titers (~106 TCID50) as determined in MDCK cells (Figure 
9B). Approximately 100 folds lower lung viral titers (8x103 TCID50) were observed in the rgH3N2 
group than those in naïve mice, which are approximately 3.5-fold higher titers than those 
(2.3x103 TCID50) in the rgH3N2 4xM2e group (Figure 9B). There was no statistical significance in 
lung viral titers between the rgH3N2 and rgH3N2 4xM2e group (Figure 9B) and a similar pattern 
of viral titers was detected when determined by EID50 in egg substrates.  
Significantly higher levels of M2e specific IgG (Figs. 9C, D) and IgA (Figs. 9D, F) antibodies 
were induced in BALF (Figs. 9C, D) and lung extracts (Figs. 9E, F) from the rgH3N2 4xM2e group 
compared to the rgH3N2 group at 5 days after infection with A/Phil. Meanwhile virus (rgH3N2, 
A/Phil) specific IgG and IgA antibodies were similarly induced in BALF and lung extracts at high 
levels in the both rgH3N2 4xM2e and rgH3N2 groups (Figs. 9C-F).  
We determined recall immune responses by measuring M2e and virus specific IgG at day 
5 or 7 post challenge with heterologous A/Phil virus (Figure 10). The rgH3N2 4xM2e primed mice 
showed significantly increased M2e specific IgG levels in sera (3-fold in OD values) (Figure 10A) 
and draining lymph nodes MLN after challenge (Figure 10D) while the other groups did not. The 
increased IgG levels specific for vaccine rgH3N2 (Figure 10B) and challenge virus A/Phil (Figure 
10C) were similarly observed in post-challenge sera from both groups. Intracellular cytokine 
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staining results indicate the induction of M2e-stimulated CD4 T cells secreting IFN-γ at high 
frequencies (Figs. 10E, F) and relatively low numbers of IFN-γ+ CD8 T cells (Figure 11) in BALF and 
lung cells from the rgH3N2 4xM2e primed mice. These results suggest that the levels of M2e 
specific antibodies and T cell immunity induced by priming rgH3N2 4xM2e in mucosal (BALF, 
lungs) and systemic (sera, MLN) sites might have contributed to cross-protection. 
 
Figure 10 Single inoculation of rgH3N2 4xM2e virus effectively primes M2e and virus 
specific immune responses 
Sera after rgH3N2 or rgH3N2 4xM2e immunization (day 14) and challenge with A/Phil H3N2 virus (50 LD50, 
day7) were collected respectively to determine IgG antibody response specific for (A) M2e (1:100 sera), 
(B) rgH3N2 (1:10,000 sera), and (C) A/Phil (H3N2) (1:10,000 sera) antigens. (D) In vitro production of M2e, 
rgH3N2, and A/Phil specific IgG antibodies in mediastinal lymph node (MLN) cell cultures. (E-F) Flow 
cytometry of intracellular cytokine staining for detection of IFN-γ secreting CD4+ T cells specific for M2e 
from BALF (E) and lung cells (F) at day 5 (D-F) or 7 (A-C) following A/Phil challenge. Error bars indicate 
mean ± SEM. The statistical significances between rgH3N2 group versus rgH3N2 4xM2e group were 




Figure 11 Measurement of M2e specific CD8+ cells secreting IFN-γ by flow cytometry    
BALB/c mice were intranasally inoculated with rgH3N2 or rgH3N2 4xM2e (105 EID50 each). IFN-γ secreting 
CD8+ cells specific for M2e were detected 5 days after A/Phil challenge (50 LD50) in BALF (A) and lung cells 
(B) from immunized mice. IFN-γ+ CD4+ T cells were presented from total BALF (1 ml) and Lung (1 ml) cells 
from individual mouse. Error bars indicate mean ± SEM. The statistical significances between rgH3N2 
group versus rgH3N2 4xM2e group were determined using one-way ANOVA and indicated in *, P < 0.05. 
 
2.4.6 Depletion of CD4 and CD8 T cells results in differential cross-protection between 
rgH3N2 4xM2e and rgH3N2 prime vaccination 
We observed substantial cross-protection by priming rgH3N2 virus even without the 
induction of M2e specific antibodies and cross HAI activities, suggesting the roles of cross-
protective T cells. Also, to determine whether M2e specific antibodies would significantly 
contribute to cross-protection, rgH3N2 or rgH3N2 4xM2e primed mice were treated with T cell 
depleting anti-CD4 or anti-CD8 antibodies prior to challenge with 25 LD50 of A/Phil (H3N2). As 
shown in Figure 12, T cells in the groups immunized with rgH3N2 or rgH3N2 4xM2e were 
effectively depleted by delivering either anti-CD4 or anti-CD8 or both antibodies prior to infection 
with A/Phil (H3N2, 17 LD50). Anti-CD4 (Figs. 13A, C) or anti-CD8 (Figs. 13B, D) antibody treatment 
resulted in significant weight loss (24% or 16% respectively) in the rgH3N2 group, lowering the 
survival rate (50% with anti-CD4, Figure 13C), compared to moderate weight loss (9.5 to 13%) in 
the rgH3N2 4xM2e group. When both CD4 and CD8 were depleted, the rgH3N2 group displayed 
significant weight loss and all mice reaching the humane endpoint (Figs. 14A, E). In contrast, 100% 
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mice from the rgH3N2 4xM2e group survived with 8% body weight loss (Figs. 14A, E). These 
results suggest that M2e antibodies contribute to cross-protection by a prime dose of rgH3N2 
4xM2e regardless of T cells at the time of challenge whereas CD4 and CD8 T cells particularly CD4 
T cells might play a significant role in cross-protection by rgH3N2. 
We extended the impact of both CD4 and CD8 depletion on cross-protection against 
A/PR8 (H1N1) and PR8 reassortants with avian M2 (Figure 14). Treatment of rgH3N2 4xM2e 
primed mice with CD4 and CD8 depleting antibodies resulted in 100% survival rates and 
approximately 13% weight loss after A/PR8 (H1N1) challenge whereas rgH3N2 primed mice 
showed over 20% weight loss and 0% survival rates (Figs. 14B, F). With CD4 and CD8 T cell 
depletion, the significant differences in weight changes and survival rates between the groups 
were observed after rgPR8 Mg challenge (Figs. 14C, G). While rgH3N2 4xM2e mice lost 9% of 
body weight with 100% survival rate, rgH3N2 mice had 20% weight loss with 20% survival rates. 
In consistent, the rgH3N2 4xM2e group showed significantly enhanced survival protection with 
less weight loss against a high lethal dose (20 LD50) of rgPR8 Ms virus (M gene from 
A/Shanghai/2/2013, H7N9) compared to the rgH3N2 group with 0% survival (Figs. 14D, H). The 
weight recovery was delayed in surviving mice with CD4 and CD8 T cell depletion after challenge, 
suggesting an important role of T cells in recovery or preventing severe viral pathology. These 
results support the differential roles of CD4 and CD8 T cells and M2e specific IgG antibodies in 
conferring cross-protection by rgH3N2 and rgH3N2 4xM2e prime immunization. 
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Figure 12 The efficacy of CD4 and CD8 T cell depletion in vaccinated mice after CD4 and 
CD8 T cell depleting antibody treatment 
(A) Schematic diagram for CD4 and CD8 T cell depleting antibody treatment schedule. (B) Flow cytometry 
profiles of CD4+ and CD8+ T cells out of total CD3+ T cells in peripheral blood mononucleocytes (PBMC). (C) 
Percentages of CD4+ T cells out of CD3+ cells, and CD8+ T cells out of total CD3+ cells in PBMC. rgH3N2: the 





Figure 13 The roles of CD4+ and CD8+ T cells in cross-protection by reassortant rgH3N2 
4xM2e prime inoculation 
The rgH3N2 or rgH3N2 4xM2e primed mice (n=4 /group) with were treated with (A, C) α-CD4 or (B, D) α-
CD8 antibodies for T cell depletion prior to A/Phil (H3N2) challenge (25 LD50).  Weight changes and survival 
rates were monitored after A/Phil challenge. Error bars indicate mean value ± SEM. The statistical 
significances between rgH3N2 group and rgH3N2 4xM2e group were determined using two-way ANOVA 
and indicated in *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
 
Figure 14 Depletion of CD4 and CD8 T cells results in differential cross-protection 
between rgH3N2 and rgH3N2 4xM2e primed mice 
The rgH3N2 or rgH3N2 4xM2e primed mice (n=4 or 5/group) were treated with α-CD4/α-CD8 antibodies 
for T cell depletion prior to influenza virus infection. (A-D) Weight changes and (E-H) survival rates were 
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monitored followed by A/Phil (H3N2) (17 LD50), A/PR8 (1.5 LD50), rgPR8 Mg (3 LD50) and rgPR8 Ms (10 LD50) 
challenge, respectively. Differential challenge doses were used depending on the subtype, pathogenicity, 
and T cell-depletion. Error bars indicate mean ± SEM. The statistical significances between rgH3N2 group 
versus rgH3N2 4xM2e group were determined using two-way ANOVA and indicated in *, P < 0.05; ***, P 
< 0.001. 
2.4.7 Boost dose of rgH3N2 4xM2e further enhances M2e antibodies 
Boost inoculation (106 EID50 rgH3N2 4xM2e) induced significantly higher levels of M2e 
specific IgG1 and IgG2a isotype antibodies (Figs. 15A, B) than post prime IgG antibody levels (Figs. 
4A, B). Consistent with post prime, hM2e IgG antibody levels post boost with rgH3N2 4xM2e 
were significantly higher than those of swine M2e or avian M2e antibodies (Figure 5B). Both 
rgH3N2 and rgH3N2 4xM2e groups increased IgG isotype antibodies and HAI activity against 
vaccine strain rgH3N2 but not against heterologous viruses including A/PR8, A/Phil, and rgH5N1 
(Figs. 16A-C) compared to prime sera. 
 
Figure 15 Boost dose of rgH3N2 4xM2e enhances cross-protection against A/Phil 
(H3N2) challenge, correlating with M2e specific IgG levels and lower inflammatory cytokine 
Sera were collected at 2 weeks after boost immunization of primed mice with rgH3N2 or rgH3N2 4xM2e. 
(A) IgG1 or (B) IgG2a antibody responses to M2e peptide. The rgH3N2 or rgH3N2 4xM2e boosted mice 
(n=4 /group) were treated with α-CD4/α-CD8 (10µg/10µg per individual) antibodies for T cell depletion 
prior to A/Phil (H3N2) challenge. (C) Weight changes of rgH3N2 or rgH3N2 4xM2e prime-boost mice after 
challenge with A/Phil (200 LD50). (D) IL-6 levels in BALF or lung extracts at day 5 post challenge with A/Phil. 
ELISA of IgG or IgA antibodies specific for M2e peptide and inactivated virus antigens (rgH3N2 or A/Phil) 
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in (E, F) BALF and (G, H) lung extracts at day 5 post challenge with A/Phil. Error bars indicate mean ± SEM. 
The statistical significances between rgH3N2 group versus rgH3N2 4xM2e group were determined using 
two-way ANOVA and indicated in *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
 
Figure 16 Intranasal boost vaccination with live rgH3N2 4xM2e virus further enhances 
rgH3N2 virus specific IgG and HAI antibodies 
Sera were collected at 2 weeks after boost immunization of primed mice with rgH3N2 or rgH3N2 4xM2e. 
(A) IgG1 or (B) IgG2a antibody detection specific for rgH3N2. (C) Boost serum HAI titers against A/PR8, 
A/Phil, rgH3N2 and A/Viet. Error bars indicate mean ± SEM.  
2.4.8 Boost dose of rgH3N2 4xM2e enhances cross-protection and correlates with higher 
M2e specific IgG levels and lower inflammatory cytokines in the respiratory sites 
At 3 weeks after boost dose, rgH3N2 and rgH3N2 4xM2e immunized mice were treated 
with T cell depleting anti-CD4 and anti-CD8 antibodies and then challenged with A/Phil H3N2 at 
a high dose. The rgH3N2 4xM2e group showed 100% protection without weight loss whereas the 
rgH3N2 group displayed substantial weight loss (15%) after A/Phil challenge (Figure 15C). 
Consistent with efficacy of cross-protection, inflammatory cytokine IL-6 levels were low in BALF 
and lung extracts from the rgH3N2 4xM2e group (Figure 15D). Significantly higher levels of M2e 
specific IgG and IgA antibodies in BALF and lung extracts were induced in the rgH3N2 4xM2e 
group than those in the rgH3N2 group after A/Phil challenge (Figs. 15E-H). Also, the levels of IgA 
antibodies specific for rgH3N2 and A/Phil viruses were higher in lung extracts from the rgH3N2 
4xM2e group than those from the rgH3N2 group (Figure 15H).  
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Consistently, boost dose of rgH3N2 4xM2e also enhanced cross-protection against 
heterosubtypic rgH5N1 virus, as shown by less weight loss (~4% versus 13% in rgH3N2 control) 
and undetectable lung viral loads (Figs. 17A, B). Particularly IgG levels specific for M2e were 
induced at significantly higher levels in BALF and lung extracts from the rgH3N2 4xM2e group 
than those in the rgH3N2 group or naïve group (Figure 17C). IgG levels to vaccine (rgH3N2) and 
challenge virus (rgH5N1) were similar in both groups. As expected, the rgH3N2 and rgH3N2 
4xM2e groups presented significantly lower amounts of TNF-α, IFN-γ and IL-6 than the naïve 
group after infection with rgH5N1 (Figure 17D). Moreover, rgH3N2 4xM2e vaccine group 
exhibited lower levels of proinflammatory cytokines (IFN-γ) compared to the rgH3N2 group.  
To determine the role and capability of immune sera in inducing cross-protection against 
heterosubtypic rgH5N1 virus, naïve mice were intranasally infected with A/Vietnam virus (2 LD50) 
after mixing with boost immune sera from the rgH3N2 and rgH3N2 4xM2e group, and naïve sera 
respectively (Figure 17E). The group with rgH3N2 4xM2e immune sera displayed significantly less 
weight loss (~3%) compared to the rgH3N2 serum group with substantial weight loss (~15%) 
similar to the naïve serum group (Figure 17E). At day 8 post challenge with rgH5N1 virus, the 
rgH3N2 group started to recover (Figure 17E). Taken together, these results indicate that M2e 
specific antibodies in mucosal and systemic sites provide cross-protection by restricting viral 
replication and preventing inflammation. 
42 
 
Figure 17 Boost with rgH3N2 4xM2e enhances cross-protection against heterosubtypic 
A/Viet rgH5N1 virus by vaccination and immune sera 
(A, B) Heterosubtypic cross-protective efficacy of boost immune mice after challenge with rgH5N1 
(A/Vietnam, 50 LD50). (A) Weight changes of boost immunized mice (n=5 /group) after rgH5N1 challenge. 
(B) Lung viral titers (TCID50 x100/ml) at 6-day post challenge with rgH5N1. (C) ELISA of IgG antibodies 
specific for M2e, rgH3N2, or rgH5N1 in BALF and lung extracts at day 6 post challenge with A/Viet rgH5N1. 
ELISA viral antigens are M2e peptide, rgH3N2 or A/Viet. (D) Inflammatory cytokines in BALF and lung 
extracts at day 6 post challenge with A/Viet rgH5N1. (E) Roles of boost immune sera in cross-protection 
against rgH5N1 virus as determined by monitoring weight changes. Naïve mice (n=3 /group) were 
intranasally inoculated with rgH5N1 (2 LD50) virus mixed with boost immune sera (rgH3N2, rgH3N2 
4xM2e) or unvaccinated naïve sera. Error bars indicate mean ± SEM. The statistical significances between 
rgH3N2 group versus rgH3N2 4xM2e group were determined using two-way ANOVA (A, C-E) or one-way 
ANOVA (B) and indicated in *, P < 0.05; **, P < 0.01; ***, P < 0.001; ###, P < 0.0005.   
 
2.5 Discussion 
The induction of strain specific neutralizing antibodies is the main immunity by current 
influenza vaccination, which is suboptimal for providing cross-protection. M2 is incorporated into 
influenza virions at a very low level (Zebedee and Lamb, 1988) and poorly immunogenic after 
vaccination or even with live virus infection (Zhong et al., 2014, Feng et al., 2006). Several 
strategies were reported in an attempt to overcome the poor immunogenicity of M2e, including 
fusion of M2e peptides to immunogenic carrier proteins and use of adjuvants (Neirynck et al., 
1999, Fan et al., 2004, De Filette et al., 2005) or delivery of VLPs containing M2e epitopes (Bessa 
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et al., 2008, Hashemi et al., 2012, Kim et al., 2013b). M2e fusion protein vaccines (M2e-HBc, M2e-
flagellins) were tested in Phase I/II clinical trials, resulting in high seroconversion inducing M2e 
specific antibody responses (Mezhenskaya et al., 2019, Deng et al., 2015). Intramuscular 
vaccination with M2e fusion protein vaccines was well tolerated except for the high doses (3 µg 
or 10 µg) of M2e-flagellin conjugates in healthy individuals (Turley et al., 2011). However, there 
has been no further clinical advancement of M2e based vaccines probably due to low efficacy of 
M2e immunity alone (Subbarao and Matsuoka, 2013, Jegerlehner et al., 2004, Song et al., 2011). 
One drawback might be short-lived M2e antibodies. Another disadvantage is the non-
neutralizing nature of M2e immunity conferring low efficacy. An approach to overcome these 
drawbacks of M2e fusion protein vaccines would be to develop chimeric influenza virus vaccines 
where multi M2e epitopes are fused to the HA molecules in a way retaining HA functional and 
immunogenic integrity. It is expected that the tolerability and protective efficacy of chimeric 
influenza virus vaccines would be compatible with seasonal vaccines in addition to providing 
extra M2e immunity.  In this approach, we generated recombinant seasonal H3N2 influenza A 
virus expressing chimeric H3 HA molecules with heterologous tandem repeat 4xM2e epitopes. 
This recombinant H3N2 virus with chimeric 4xM2e-HA was found to be highly attenuated, 
effective in inducing both M2e and HA immunity, conferring cross-protection against different 
viruses H1N1, reassortants with avian M2, H3N2, H5N1, H7N9, and H9N2 subtypes in mice with 
a single dose.  
The comparable in vitro growth kinetics of rgH3N2 4xM2e viruses suggest the integrity of 
HA functions in recombinant H3N2 virus containing chimeric H3 4xM2e-HA. The pathogenicity of 
rgH3N2 reassortants (up to 106 EID50) with the PR8 backbone was highly attenuated in mice by 
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1,000 to 10,000 folds in the aspects of weight changes and viral replication (103 versus 108 EID50 
titers) in the lungs compared to the WT A/PR8 (H1N1) virus (104 EID 50). The attenuated rgH3N2 
phenotypes might serve as an appropriate platform to test vaccine candidates in mice. Owning 
to the attenuated phenotypes, a single prime dose of rgH3N2 4xM2e within a typical range (105 
– 106 EID50) for LAIV vaccination (Kotomina et al., 2019, Isakova-Sivak et al., 2017) could mimic 
vaccination without displaying pathogenic phenotypes. Chimeric rgH3N2 4xM2e was not 
defective in inducing immunity to virus.   
It is significant to observe substantial levels of IgG isotype antibodies specific for M2e 
after prime with recombinant seasonal rgH3N2 4xM2e virus compared to WT rgH3N2 virus. The 
rgH3N2 4xM2e primed mice were protected against H1N1 A/PR8 and rgH9N2 virus as shown by 
100% survival rates and relatively quicker recovery than the rgH3N2 group with 0 to 30% survival 
rates. Also, prime dose of rgH3N2 4xM2e provided higher protection with minimum weight loss 
against lethal challenge with H3N2 A/Phil, rgH5N1, and rgH7N9 virus although rgH3N2 primed 
mice survived in the absence of inducing cross reactive HAI activity. The efficacy of cross-
protection by priming with rgH3N2 4xM2e appears to be correlated with enhanced levels of M2e 
IgG antibodies in sera and mucosal (BALF, lungs) sites as well as IFN-γ secreting CD4 T cells (Figs. 
10E, F).  
The rgH3N2 control group showed substantial protection against H1N1, rgH5N1, rgH7N9, 
and rgH9N2 virus and A/Phil (H3N2) virus in the absence of cross-reactive HAI titers, lowering 
100 folds in lung viral titers compared to mock control mice after infection. With CD4 or CD8 T 
cell depletion, the differences in cross-protection against H3N2 A/Phil and H1N1 A/PR8 viruses 
were more evident between the rgH3N2 and rgH3N2 4xM2e primed mice. Also, the survival rates 
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were lower particularly in the rgH3N2 group and recovery was delayed under a condition of both 
CD4 and CD8 T cell depletion even after low challenge doses with group 1 H1N1 virus A/PR8 and 
reassortants. These results support the significant roles of cross protective T cells particularly 
during a recovery phase. It is also possible that HA stalk specific antibodies induced in both 
chimeric 4xM2e-HA and WT rgH3N2 virus groups would contribute to cross-protection against 
group 2 viruses with relatively high doses. This cross-protection observed in the control rgH3N2 
group, despite significantly lower efficacy than rgH3N2 4xM2e, indicates a caveat in testing 
vaccine efficacy of live recombinant influenza viruses in mouse models. Consistent, the mice 
surviving pathogenic influenza virus infection were reported to confer heterosubtypic cross-
protection (Kim et al., 2017a, Guo et al., 2011, O'Neill et al., 2000).  
The levels of M2e specific IgG antibodies were significantly increased post boost with live 
rgH3N2 4xM2e virus, indicating effective priming of B cells by the first dose. In line with this 
outcome, enhanced cross-protection against A/Phil H3N2 virus was observed in the rgH3N2 
4xM2e group displaying no apparent weight loss after boost compared to the rgH3N2 control. 
Use of higher dose (50 LD50) challenge is because of prime-boost vaccination and the same 
subtype as the rgH3N2 vaccine strain. When challenged with heterosubtypic rgH5N1 virus, the 
increases in M2e specific IgG responses in BALF and lungs but not IgG responses to rgH5N1 were 
higher than those with homosubtypic A/Phil H3N2 challenge. Consistently, BALF and lungs 
showed highly enhanced levels of IgG and IgA antibodies specific for M2e, compared to the 
control group.  
A recent study reported that inactivated chimeric influenza viruses containing an M2e 
epitope in the immunodominant head site of HA could induce IgG antibodies to M2e and stalk 
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domains after intramuscular vaccination, conferring cross-protection (Sun et al., 2019, Kim et al., 
2020). The size of foreign epitopes or fragments to be inserted into the N-terminus of HA appears 
to be highly flexible as large as 246 residues while maintaining HA functional (Hatziioannou et al., 
1999). Whereas recombinant influenza viruses containing the only a limited length of foreign 
epitopes less than 18 residues in the HA head domain could be rescued to generate replication-
competent viruses (Lee et al., 2016a, Garcia-Sastre and Palese, 1995). The location of inserting 
foreign epitopes in HA molecules should be considered in the size of epitopes and routes of 
vaccination.  
The non-neutralizing immune mechanisms of protection by M2e antibodies were 
reviewed (Deng et al., 2015, Mezhenskaya et al., 2019, Lee et al., 2015a) in addition to M2e T cell 
contributions. Previous studies reported that M2e vaccine immune sera did not exhibit 
neutralization activity by plaque reduction or tissue culture infectivity assays (Deng et al., 2018, 
Jegerlehner et al., 2004). Mechanisms of protection by passive transfer of M2e antibodies include 
antibody dependent cell-mediated cytotoxicity and antibody dependent cell-mediated 
phagocytosis, which involves Fc receptors, complements, natural killer (NK) cells, and 
macrophages. Passive transfer of M2e vaccine immune sera prior to virus infection provides 
survival advantages (Wang et al., 2014). The infection of naïve mice with a mix of challenge virus 
and sera required smaller amounts of sera than the passive transfer of sera prior to infection. 
Our current and previous studies indicate that both simultaneous mix and prior-to-infection 
passive transfer approaches produced similar outcomes. We previously reported that the efficacy 
of M2e immune sera was significantly reduced or abrogated in Fcγ receptor knockout mice, 
suggesting a critical role of Fcγ receptors in mediating M2e antibody mediated protection (Kim 
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et al., 2013a, Kim et al., 2017b, Lee et al., 2014a). M2e antibody-dependent NK cell activity was 
reported to be important for M2e immune mediated protection (Jegerlehner et al., 2004). 
In summary, recombinant seasonal influenza rgH3N2 4xM2e virus containing tandem 
repeat 4xM2e epitopes in the N-terminus of HA molecules retains comparable growth properties 
in vitro and LAIV-like attenuation phenotypes in vivo in mice. Intranasal prime vaccination with 
rgH3N2 4xM2e virus could provide broad and enhanced cross-protection against different 
subtypes H1N1, H3N2, rgH5N1, rgH7N9, and rgH9N2 as well as reassortant viruses with avian 
M2. In vivo limited replication of recombinant influenza virus containing foreign epitopes in the 
N-terminus HA appears to be an attractive strategy to induce systemic and mucosal immune 
responses to the inserted epitopes. This study provides insight into developing broad cross-
protective recombinant influenza virus vaccines.  This approach of recombinant influenza virus 
vaccine platforms with a licensed master backbone should be further tested in ferrets, a more 
relevant animal model in future studies. 
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3.1 Abstract 
Annual repeat influenza vaccination raises concerns about protective efficacy against 
mismatched viruses. We investigated the impact of heterologous prime-boost vaccination on 
inducing cross-protection by designing recombinant influenza viruses with chimeric 
hemagglutinin (HA) carrying M2 extracellular domains (M2e-HA). Heterologous prime-boost 
vaccination of C57BL/6 mice with M2e-HA chimeric virus more effectively induced M2e and HA 
stalk specific IgG antibodies correlating with cross protection than homologous prime-boost 
vaccination. Induction of M2e and HA stalk specific IgG antibodies was compromised in 1-year 
old mice, indicating significant aging effects on priming subdominant M2e and HA stalk IgG 
antibody responses. This study demonstrates that a heterologous prime-boost strategy with 
recombinant influenza virus expressing extra M2e epitopes provides more effective cross-
protection than homologous vaccination. 
3.2 Introduction 
Influenza A virus belongs to the Orthomyxoviridae family, a negative-sense single-
stranded RNA virus containing eight segmented genomes. It has a wide variety, originating from 
18 hemagglutinin (HA) subtypes (H1-H18) and 11 neuraminidase (NA) subtypes (N1-N11), with 
antigenically diverse strains isolated in each subtype (Tong et al., 2013). Hundreds of millions of 
people are infected yearly with influenza viruses, which leads to 290,000 to 646,000 deaths 
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globally, with young children and the elderly being the most vulnerable (Iuliano et al., 2018, Lee 
et al., 2018, Thompson et al., 2003).  
Due to the emergence of drifting mutations and pandemics, overall vaccine effectiveness 
is in a wide range of low efficacy between 10 % and 60 % (CDC, 2021e). Low vaccine effectiveness 
comes from multiple factors such as aging, health and pre-existing immune status, antigenic 
mismatches, and poor immunogenicity of vaccines. Vaccine strains are annually updated to 
reflect better the circulating influenza strains and vaccination is recommended every year. While 
annually repeated influenza vaccination was effective with variable efficacy (Casado et al., 2018, 
Mastalerz-Migas et al., 2015a, Beyer et al., 1999, Smith et al., 1999, de Bruijn et al., 1999, Keitel 
et al., 1997), several recent studies have indicated that repeated annual vaccination did not result 
in improving vaccine effectiveness particularly when circulating strains are mismatched (McLean 
et al., 2014, Leung et al., 2017, Morimoto and Takeishi, 2018, Song et al., 2020). It has been a 
high priority to enhance the vaccine efficacy and develop broadly cross-protective vaccines.  
Influenza virus HA proteins consist of the immune-dominant but highly variable head 
domain, which provides a strain-specific neutralizing target, as well as the relatively conserved 
stalk domain, which mediates the viral membrane fusion (Krammer et al., 2018a). To overcome 
the immune-subdominant nature of HA stalk domains, influenza viruses were reverse-genetically 
engineered to contain chimeric HA where the variable head domain was replaced with a 
corresponding domain from the antigenically far distant strains without changing the stalk 
domain (Nachbagauer et al., 2021, Liao et al., 2020). Recombinant chimeric HA influenza virus 
vaccines were reported to induce high levels of stalk specific IgG responses leading to enhanced 
cross-protection in animal models (Krammer et al., 2013). In phase I clinical studies, AS03-
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adjuvanted chimeric HA-based influenza virus vaccine induced durable IgG responses to the HA 
stalk domain (Nachbagauer et al., 2021, Bernstein et al., 2020). While these results provide a 
proof-of-concept for developing stalk-based cross-protective vaccines, they would not confer 
sufficient protection against currently circulating strains due to their antigenically unrelated HA 
head domain. 
Influenza A virus contains ion channel protein M2 extracellular epitopes (M2e) which are 
highly conserved but poorly immunogenic, despite being a promising universal antigenic target 
(Saelens, 2019). To induce immunity to both M2e and circulating HA, replication-competent 
influenza viruses were genetically modified to retain and express chimeric HA molecules with 
tandem repeat 4xM2e in the N-terminus HA (4xM2e-HA) from H1N1 (Kim et al., 2017a), H3N2 
(Park et al., 2021), and H7N9 virus (Mezhenskaya et al., 2021a). The live recombinant 4xM2e-HA 
influenza virus vaccines were immunogenic in inducing strain specific neutralizing antibodies and 
M2e immunity, conferring differential cross protection in BALB/c mice. However, the efficacy of 
homologous prime-boost vaccination would likely be limited due to pre-existing immunity. 
The impact of heterologous prime-boost vaccination with recombinant 4xM2e-HA 
influenza virus vaccines and pre-existing immunity on inducing cross-protection against influenza 
viruses remains unknown. In this study, we investigated the efficacy of cross-protection by 
heterosubtypic prime-boost vaccination with live recombinant 4xM2e-HA H1N1 and H3N2 
influenza virus vaccines in C57BL/6 mice that are known to be a less responder to low 
immunogenic conserved epitopes. Heterologous prime-boost strategies using recombinant 
4xM2e-HA influenza virus vaccines were found to be more effective in inducing cross-protection 
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against antigenically different viruses in C57BL/6 mice compared to homologous prime-boost 
vaccination strategies. M2e and HA stalk immunity might have played a role in cross-protection. 
 
3.3 Materials and Methods 
3.3.1 Cells and viruses 
293T cells (ATCC) were cultured in Dulbecco’s Modified Eagle Medium media (DMEM) 
and used for plasmid DNA transfection. Influenza viruses were amplified in embryonated chicken 
eggs (Hy-Line N.A., Mansfield, GA) and confirmed to be free of the influenza virus. A/Puerto 
Rico/8/34 (A/PR8, H1N1), A/California/04/09 (A/Cal, H1N1), A/Philippines/2/82 (A/Phil, H3N2), 
and A/Vietnam rgH5N1 (A/Viet, rgH5N1) virus were used, which possesses HA (polybasic residues 
removed) and NA from A/Vietnam/1203/2004 and 6 other backbone genes of A/PR8 as 
previously described(Song et al., 2011). H3N2 recombinant virus was a reassortant virus with 
A/PR8 backbone (X-247 rgH3N2, International Reagent Resource, FR-1366) carrying HA and NA 
genes from A/Switzerland/9715293/2013. The influenza viruses were propagated in 10-day-old 
embryonated chicken eggs and inactivated by treatment of 37% formalin at 1:4,000 (v/v) 
dilutions as described previously (Quan et al., 2008). 
3.3.2 Construction of attenuated A/PR8 backbone H1N1 and H3N2 viruses expressing 
chimeric 4xM2e-HA 
Recombinant influenza viruses carrying wild type or chimeric hemagglutinin (HA) were 
generated using reverse genetics with PR8 backbone genes within the pHW2000 plasmids (kindly 
provided by Dr. Robert G. Webster, St. Jude Children’s Research Hospital). The attenuated PR8 
backbone (attPR8) was generated by introducing mutations in the PB1 (K391E, E581G, A661T) 
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and PB2 (N265S) polymerase genes granting temperature-sensitive (ts) attenuation as described 
(Jung et al., 2020). Reassorted H3N2 virus contained HA and NA genes derived from 
A/Switzerland/9715293/2013 (H3N2). The chimeric 4xM2e-HA genes encoded for four tandem 
repeats of M2e (4xM2e composed of 2x human M2e, swine M2e and avian M2e) inserted into 
the N-terminus of A/PR8 H1 HA (4xM2e-HA H1) (Kim et al., 2017a) or A/Switzerland H3 HA 
(4xM2e-HA H3, Figure 18A) as previously described (Park et al., 2021). The 4xM2e-HACal head 
construct contained A/Cal HA head domain (Cys52-Cys277) in the 4xM2e-HA H1 context replacing 
the A/PR8 HA head domain (Figs. 18A, B). Eight plasmids encoding A/PR8 backbone plus each 
gene segment, including the desired subtype 4xM2e-HA construct and NA were co-transfected 
into 293T cells and incubated for 2 days. Chicken embryonated eggs were inoculated with 
transfection supernatants to rescue different subtype chimeric 4xM2e-HA recombinant viruses. 
The rescue of recombinant influenza virus was initially confirmed by measuring hemagglutination 
activity of egg allantoic fluids. 
3.3.3 Characterization and pathogenicity assessment of recombinant viruses 
Recombinant viruses rescued were characterized by measuring replication titers in 
embryonated chicken eggs (50% egg infectious dose, EID50) and hemagglutination activity using 
0.5% chicken red blood cells (RBC, Lampire Biological Laboratories). The existence of 4xM2e in 
HA was confirmed with enzyme-linked immunosorbent assay (ELISA) using M2e specific 
monoclonal antibody (14C2 mAb) (Abcam Inc., Cambridge, MA). To assess the pathogenicity of 
recombinant viruses, C57BL/6J mice were intranasally infected with 106 EID50 of attPR8, attPR8 
with 4xM2e-HA H1 (attPR8 4xM2e) or 5x105 of EID50 of H3N2 or H3N2 with 4xM2e-HA H3 (H3N2 
4xM2e), and body weight changes were monitored. Moreover, nasal turbinates and lung tissue 
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samples were collected and homogenized in RPMI media at 3 days after intranasal infection with 
104 EID50 of A/PR8, PR8 with 4xM2e-HACal head (Cal 4xM2e) or 106 EID50 of attPR8, attPR8 4xM2e 
H3N2 or H3N2 4xM2e. Serially diluted supernatants were inoculated in the embryonated eggs to 
determine virus titers. 
3.3.4 Immunization and influenza virus challenge in mice 
C57BL/6J mice received sequential prime-boost intranasal immunizations with 
recombinant live viruses in an interval of 3 weeks. The first set of mice groups (n = 20 /group, 6-
8 weeks old, Jackson Laboratories) were intranasally primed with 106 EID50 of attPR8 or attPR8 
4xM2e H1N1 viruses and boosted with 106 EID50 of attPR8, attPR8 4xM2e, H3N2, H3N2 4xM2e 
or 105 EID50 of Cal 4xM2e H1N1 viruses. One-year-old C57BL/6J mice (n =5) were primed with 
attPR8 4xM2e (106 EID50) and boosted with H3N2 4xM2e (106 EID50). For reverse order 
immunization, mice (n = 20 /group, 6-8 weeks old, Jackson Laboratories) were intranasally 
vaccinated with 5x105 EID50 of H3N2 or H3N2 4xM2e and boosted with 106 EID50 of H3N2, attPR8 
or attPR8 4xM2e H1N1 viruses. Mouse blood samples were collected through retro-orbital 
bleeding 2 weeks after each immunization. Mouse groups, including naïve group (unvaccinated 
mice) from the H1N1 primed set and H3N2 primed another set of hetero prime-boost 
immunizations, were challenged with A/Viet rgH5N1 (10 LD50, 1.6 x 106 EID50) and A/Phil (100 
LD50, 1.4 x104 EID50) respectively. All animal experiments in this study were approved by the 
Georgia State University Institutional Animal Care and Use Committee (IACUC) review boards. 
Mouse animal experiments including virus infection, blood collection, and tissue collections were 
performed in accordance with the approved IACUC protocol (A21004) and regulations. 
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3.3.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
IgG antibodies specific for the viruses were measured by ELISA with coating antigens (4 
μg/ml) from inactivated A/PR8 H1N1, A/Cal H1N1, A/SW H3N2, A/Phil H3N2, and A/Viet rgH5N1 
viruses. M2e-specific IgG antibody responses were determined using M2e peptide antigen (23 
amino acids) as described previously (Kim et al., 2013b, Kim et al., 2014). Construction and 
preparation of the consensus group 1 stalk and group 2 stalk proteins were previously reported 
(Chae et al., 2019) and used as coating antigens for measuring HA stalk specific IgG antibodies. 
To determine IgG antibodies to both M2e and HA stalk domains, chimeric M2e-H1 HA stalk 
protein (aa1-117 of HA2 domain from A/PR8 virus) and M2e-H3 stalk protein (aa1-117 of HA2 
domain from A/Aichi/1968 H3N2 virus) were expressed in E. Coli and purified (Jeeva at al., 
unpublished data) and used as an ELISA coating antigen. HRP (Horseradish Peroxidase) 
conjugated goat anti-mouse IgG (Southern Biotechnology) was used as a secondary antibody. 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Invitrogen™) was utilized for color 
development. IgG antibody levels were read by BioTek ELISA plate reader at 450nm. 
3.3.6 Hemagglutination Inhibition (HAI) Titers 
Mouse sera were treated with receptor destroying enzymes (RDE, Sigma) with a 1:4 ratio, 
incubated at 37 °C overnight, and inactivated at 56°C for 30 minutes. RDE-treated serum samples 
were serially diluted (two-fold) and incubated with an equal volume of viruses (4 
hemagglutination activity units). HAI titers were measured with 0.5% RBC. 
3.3.7 Preparation of lung samples 
Lung lysates and bronchoalveolar lavage fluids (BALFs) were collected on day 5 after the 
challenge. Lung extracts were obtained from the lung homogenates in 1.5ml of RPMI media after 
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centrifugation and used to determine virus titers in embryonated chicken eggs, IgG antibody 
responses specific for M2e, M2e-H1 stalk and M2e-H3 stalk were measured. BALFs were 
harvested by infusing 1ml of phosphate-buffered saline (PBS) into the trachea. IL-6 cytokine levels 
from BALFs and lung extracts were determined by Ready-SET-Go kits with IL-6 specific antibodies 
(eBioscience, San Diego, CA) according to the manufacturer’s instructions. 
3.3.8 Antibody-dependent cell-mediated cytotoxicity (ADCC) analysis 
ADCC in immune sera was quantified by ADCC Reporter Bioassay Kit (Promega Life 
Sciences). The target MDCK cells (4x104/100ul/well) on the 96-well Optical-Bottom plates 
(Thermo Scientific™) were infected with 100x TCID50 of A/Viet rgH5N1 or A/Phil H3N2 virus one 
day prior to assay. Infected cells were washed with 200 µL RPMI medium (Thermo Fisher 
Scientific) and supplemented with 25 µL assay buffer (containing 4% low IgG serum in RPMI 
medium provided by assay kit). Heat-inactivated immune sera (25 µL) diluted in assay buffer were 
added to the cells and then further incubated for 6 h at 37 °C following the treatment of mouse 
effector Jurkat cells (Promega Life Sciences, 75,000 cells/well). Fluorescence was read by a 
Cytation 5 imaging reader (BioTek) after 5-min incubation at room temperature with 75 µL /well 
of Bio-Glo luciferase assay substrate (Promega Life Sciences). The fold induction was calculated 
after subtracting the culture medium background as suggested in the technical manual. The 
measurements were conducted in triplicate using three replicate wells. 
3.3.9 Statistical analysis 
Statistically significant differences were determined among groups using two- or one-way 
ANOVA. A ρ-values that were less than or equal to 0.05 were considered statically significant. 
Data were analyzed using Prism software (GraphPad Software Inc., San Diego, CA). 
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3.4 Results 
3.4.1 In vitro and in vivo virological characterization of recombinant influenza viruses 
containing chimeric 4xM2e-HA 
The rescued recombinant influenza viruses containing chimeric HA where foreign gene 
fragments were genetically linked to the N-terminus of HA were reported to be highly stable even 
after 10 passages (Kim et al., 2017a, Park et al., 2021, Lee et al., 2015b, Mezhenskaya et al., 
2021a). The rescued recombinant live attenuated influenza viruses H1N1 (A/South 
Africa/3626/2013), H3N2 (А/Switzerland/9715293/2013), and H7N9 (А/Anhui/1/2013) 
containing 4xM2e-HA were confirmed by sequencing the full-length HA in previous studies 
(Kotomina et al., 2020, Mezhenskaya et al., 2021a). To determine the impact of heterologous 
prime-boost vaccination on cross-protection, we generated three different recombinant 
influenza A viruses containing tandem repeat 4xM2e-HA (Figure 18A). The attPR8 4xM2e is an 
A/PR8 reassortant virus with an attenuated backbone and chimeric 4xM2e-HA H1 of A/PR8. The 
Cal 4xM2e virus contains the A/PR8 wild type backbone and 4xM2e-HA where the head domain 
(C52-C277) of A/PR8 H1 HA was replaced with that of A/California/2019 (A/Cal). The reassortant 
H3N2 and H3N2 4xM2e viruses contain HA and 4xM2e-HA respectively, H3 HA and N2 NA genes 
from A/Switzerland/2013 (A/SW, H3N2) and the internal and A/PR8 wild type backbone as 
previously described (Park et al., 2021). The prediction of structural modeling of 4xM2e-HA 
chimera indicates similarity in displaying the globular head domain, stalk domain, and tandem 
repeat 4xM2e linked to the N-terminus of HA and juxtaposed to the bottom of the stalk (Figure 
18B). These recombinant viruses propagated in embryonated chicken eggs retained high 
infectious titers (Figure 18C). The Cal 4xM2e, A/SW H3N2, and H3N2 4xM2e viruses showed 
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approximately 4 folds lower hemagglutination activity units (HAU), compared to those of A/PR8, 
attPR8, and attPR8 4xM2e viruses respectively (Figure 18D). M2e epitopes in attPR8 4xM2e, 
H3N2 4xM2e, and Cal 4xM2e viruses were detected at significantly higher levels compared to 
those of corresponding viruses with unmodified HA (Figure 18E).  
 
Figure 18 In vitro characterization of recombinant influenza viruses containing M2e 
epitopes (4xM2e) in chimeric HA conjugates 
(A) Constructs of chimeric hemagglutinin (HA) carrying 4xM2e in its N-terminus. 4xM2e-HA H1: A/PR8 H1 
HA containing 4xM2e, 4xM2e-HACal head: A/PR8 4xM2e-HA head domain (Cys52-Cys277) was replaced with 
A/Cal HA head domain, 4xM2e-HA H3: A/SW H3 HA carrying 4xM2e. SP: signal peptide, tandem repeat 
4xM2e is composed of human M2e (SLLTEVETPIRNEWGSRSNDSSD), swine M2e 
(SLLTEVETPTRSEWESRSSDSSD), and avian M2e (SLLTEVETPTRNEWESRSSDSSD). L and C represent linker 
(AAAGGAA) and connector (AAAPGAA). (B) Predictive three-dimensional structure of the chimeric HA 
monomers for 4xM2e-HA H1, 4xM2e-HACal head and 4xM2e-HA H3 respectively, utilizing PyMol program. 
(C) Titration of infectious viruses in allantoic fluids of embryonated eggs inoculated with A/PR8, attPR8, 
attPR8 4xM2e, Cal 4xM2e, H3N2, or H3N2 4xM2e virus. (D) Hemagglutination activity in recombinant virus 
stocks using chicken RBC. (E) Reactivity of recombinant virus to M2e specific mAb 14C2. Error bars indicate 
mean ± SEM. 
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To test the pathogenicity of recombinant viruses, body weight changes were monitored 
in C57BL/6J mice after intranasal inoculation with attPR8 (106 EID50), attPR8 4xM2e (106 EID50), 
H3N2 (5x105 EID50) or H3N2 4xM2e (5x105 EID50) at the doses used as prime vaccination. No body 
weight loss was detected in all groups (Figure 19A). In addition, no weight loss was observed in 
the mice intranasally primed with 106 EID50 of attPR8 or attPR8 4xM2e and homo- or 
heterologous boost with 106 EID50 of attPR8, H3N2, attPR8 4xM2e, or H3N2 4xM2e, or 105 EID50 
of Cal 4xM2e (Figure 19B).  
Infectious titers of virus replication in upper (nose) and lower (lung) respiratory tracts 
were determined at 3 days after intranasal inoculation of mice with A/PR8, attPR8, attPR8 
4xM2e, Cal 4xM2e, H3N2 or H3N2 4xM2e (Figure 19C). The wild type A/PR8 and Cal 4xM2e 
viruses replicated at higher titers in lung lysates than in nasal turbinates by 102 and 106 folds, 
respectively. In contrast, attPR8, attPR8 4xM2e, H3N2, and H3N2 4xM2e viruses were detected 
at higher virus titers in the nasal turbinates than in the lung by approximately 104, 102, 10 and 
102 folds respectively (Figure 19C), confirming their attenuated phenotypes. 
 
Figure 19 Pathogenicity of recombinant influenza viruses in mice   
(A) Body weight changes of C57BL/6J mice (n = 8-24/group) after intranasal inoculation with live attPR8 
(106 EID50), attPR8 4xM2e (106 EID50), H3N2 (5x105 EID50) or H3N2 4xM2e (5x105 EID50). (B) Body weight 
changes in C57BL/6J mice (n = 5-9/group) prime boost immunized with attPR8/attPR8, attPR8/H3N2, 
attPR8 4xM2e/attPR8 4xM2e, attPR8 4xM2e/H3N2 4xM2e and attPR8 4xM2e/Cal 4xM2e. 106 EID50 of 
these viruses were inoculated except for Cal 4xM2e (105 EID50). (C) Virus replications in mouse lung and 
nasal turbinate (n = 4-5) at day3 post challenge with A/PR8 (104 EID50), attPR8 (106 EID50), attPR8 4xM2e 
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(106 EID50), Cal 4xM2e (104 EID50), H3N2 (106 EID50) and H3N2 4xM2e (106 EID50).  Each individual animal 
is analyzed. Error bars indicate mean ± SEM. 
3.4.2 H1N1 virus prime and heterologous boost with recombinant viruses carrying 
4xM2e-HA induces enhanced M2e specific IgG and differential levels of HA stalk 
specific IgG antibodies 
We determined the impact of heterologous boost in mice primed with H1N1 virus 
(attPR8+/-M2e) on inducing a profile of IgG antibodies for homo and hetero viruses, M2e, and 
HA stalk domains, in a set of five groups. The groups consisted of attPR8/attPR8, attPR8/H3N2, 
attPR8 M2e/attPR8 M2e, attPR8 M2e/H3N2 M2e and attPR8 M2e/Cal M2e where M2e indicates 
4xM2e in the vaccine groups (Figure 20A). Intranasal prime inoculation of C57BL/6J mice with 
attPR8 or attPR8 M2e induced IgG antibodies to homologous A/PR8 at substantial levels and 
cross-reactive IgG antibodies to A/SW H3N2 and rgH5N1 reassortant viruses at lower levels 
(Figure 21). M2e and group 1 stalk specific IgG antibodies were induced at very low levels after 
prime dose attPR8 M2e, suggesting that M2e and HA stalk domains are immuno-subdominant 
(Figure 21). Heterosubtypic boost (attPR8 M2e/H3N2 M2e) induced highest levels of IgG 
antibodies specific for M2e followed by the heterologous boost group (attPR8 M2e/Cal M2e) 
(Figure 20B). Homo- and heterologous boost groups showed similar levels of IgG antibodies to 
A/PR8, A/Cal H1N1, and A/Viet rgH5N1 viruses (Figs. 20C, E, F). The attPR8/H3N2 and attPR8 
M2e/H3N2 M2e vaccinated groups induced an increased level of IgG antibodies to A/SW H3N2 
virus than other groups (Figure 20D). Meanwhile, the heterologous attPR8 M2e/Cal M2e group 
induced the highest levels of consensus group 1 stalk IgG responses (Figure 20G). Also, the group 
boosted with H3N2 or H3N2 M2e showed the highest IgG antibody reactivities to consensus 
group 2 stalk domain as expected (Figure 20H). These results suggest that a strategy of hetero 
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boost vaccination is more effective in inducing IgG antibodies specific for M2e and HA stalk 
immuno-subdominant epitopes.  
The immunogenicity of hetero boost attPR8 M2e/H3N2 M2e was tested in one-year-old 
C57BL/6J mice after intranasal vaccination (Figure 22). Prime dose of attPR8 M2e induced 
substantial levels of IgG antibodies for A/PR8 H1N1, H3N2 (A/SW), and rgH5N1, but M2e and HA 
stalk IgG antibodies were detected at very low levels (Figure 22). After H3N2 M2e boost in aged 
C57BL/6J mice (attPR8 M2e/H3N2 M2e, Figure 23), IgG antibodies to M2e, A/PR8, H3N2, and 
rgH5N1 viruses but not to HA stalk domain were induced at increased levels despite lower levels 
being induced compared to those in young adult mice (Figure 20). These data implicate that 





Figure 20 IgG antibodies specific for M2e, different viruses, and HA stalk domains after 
hetero boost with recombinant viruses in H1N1 primed 
(A) Timeline strategy of hetero prime-boost intranasal immunization with recombinant viruses. C57BL/6J 
mice received prime vaccination with 106 EID50 of attPR8 H1N1 or attPR8 M2e H1N1 were inoculated with 
106 EID50 of attPR8, attPR8 M2e, H3N2 M2e, or 105 EID50 of Cal M2e in a 3-week interval (n = 8/each 
group). M2e indicates chimeric 4xM2e-HA. Serum IgG antibody responses specific for M2e peptide (B), 
A/PR8 virus (C), H3N2 virus (D), A/Cal virus (E), A/Viet virus (F), consensus group 1 stalk (G), and consensus 
group 2 stalk (H). Mouse sera were collected at 2 weeks after prime-boost immunization. attPR8/attPR8: 
homologous prime-boost attPR8 H1N1, attPR8/H3N2: heterosubtypic attPR8 prime and A/SW H3N2 
boost, attPR8 M2e/attPR8 M2e: heterosubtypic prime-boost with chimeric 4xM2e-HA viruses, and attPR8 
M2e/Cal M2e: heterologous H1N1 prime-boost with chimeric 4xM2e-HA viruses. M2e in the vaccine 





Figure 21 IgG antibodies specific for M2e, viruses, and HA stalk domains after prime 
dose immunization with attPR8 or attPR8 M2e 
C57BL/6J mice (6-8 weeks, n = 13-19) were intranasally inoculated with 106 EID50 of attPR8 or attPR8 M2e. 
Serum IgG antibody responses at 2 weeks after prime specific for M2e (A), A/PR8 Virus (B), H3N2 virus (C), 
A/Cal virus (D), A/Viet virus (E), consensus group 1 stalk protein (F), and consensus group 2 stalk protein 
(G). Each individual mouse sera were analyzed. Error bars indicate mean ± SEM. The statistical 
significances were determined using two-way ANOVA and indicated in **, P < 0.01. 
 
 
Figure 22 IgG antibody responses in 1-year-old mice after attPR8 or attPR8 M2e 
vaccination  
Sera samples were collected at 2 weeks after attPR8 or attPR8 M2e immunization in 1-year-old C57BL/6J 
mice (n = 5). IgG antibody detection to M2e (A), A/PR8 virus (B), H3N2 virus (C), A/Viet virus (D), consensus 
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group 1 stalk protein (E) and consensus group 2 stalk protein (F). Each individual mouse sera were 
analyzed. Error bars indicate mean ± SEM. The statistical significances were determined using two-way 
ANOVA and indicated in *, P < 0.1; **, P < 0.01; ***, P < 0.001. 
 
 
Figure 23 IgG antibodies specific for M2e, different viruses, and HA stalk domains in 1 
year old C57BL/6J mice after attPR8 M2e prime and H3N2 M2e boost  
IgG antibody immune responses to M2e peptide (A), A/PR8 virus (B), H3N2 virus (C), A/Viet virus (D), 
consensus group 1 stalk protein (E), and consensus group 2 stalk protein (F). One year old C57BL/6J mice 
(n = 4) were inoculated with 106 EID50 of attPR8 M2e and H3N2 M2e in a 3-week interval and bled at 2 
weeks after boost. Each individual animal is analyzed. Error bars indicate mean ± SEM. 
 
3.4.3 Strain specific HAI titers were induced by heterosubtypic prime boost chimeric 
recombinant influenza virus vaccination 
Prime dose of attPR8 M2e induced A/PR8 specific hemagglutination inhibition (HAI) titers 
at approximately 2 folds lower than attPR8 in young adult mice and 4 folds higher than that in 1-
year old mice (Figure 24A). Homologous boost with attPR8 and attPR8 M2e increased HAI titers 
against A/PR8 virus by 4 folds in young adult mice whereas hetero boost with H3N2 M2e (attPR8 
M2e/H3N2 M2e) induced 2 folds increases in A/PR8 HAI titers, but not by Cal M2e boost or in 1-
year old mice (Figs. 24A, B). High HAI titers against H3N2 (A/SW) were induced by hetero boost 
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with H3N2 or H3N2 M2e in young adult mice, which were approximately 20 folds higher than in 
1-year-old mice with H3N2 M2e boost. No cross HAI titers against rgH5N1 virus were detected in 
young adult and aged mice after vaccination (Figure 24B). 
 
Figure 24 HAI titers against hetero prime and boost viruses  
(A) HAI titers against A/PR8 virus in young adult and 1-year old mouse sera after prime dose (106 EID50) of 
attPR8 or attPR8 M2e. (B) HAI titers against A/PR8 H1N1, A/SW H3N2, and A/Viet rgH5N1 viruses after 
hetero boost in young adult and 1-year-old mice. Mouse sera were collected at day 14 following 
immunization. Group labels are the same as in the Figure 20 legend. Each individual mouse sera were 
analyzed (n = 8/group). Error bars indicate mean ± SEM. 
3.4.4 Hetero boost with recombinants 4xM2e-HA viruses in H1N1 M2e primed mice 
improves cross protection against rgH5N1 virus 
To investigate cross protective efficacy, mice were challenged with A/Viet rgH5N1 virus 
at a lethal dose 3 weeks after boost immunization (Figure 25A). The hetero boost groups (attPR8 
M2e/H3N2 M2e and attPR8 M2e/Cal M2e) presented similarly least weight loss (~4.2%) whereas 
the homo boost groups (attPR8/attPR8 and attPR8 M2e/attPR8 M2e) displayed substantial 
weight loss, 10% and 12% respectively (Figure 25A). In an additional experimental set to 
determine lung viral titers, the hetero boost attPR8 M2e/H3N2 M2e group showed slight weight 
loss (~4%) by day 3 post challenge, they began to recover by day 4 when lung viral loads were 
reduced to a minimum of 105 folds lower than the titer in naive mice (107 EID50/ml) after infection 
with rgH5N1 virus (Figs. 25B, C). Meanwhile, the homo boost attPR8 M2e/attPR8 M2e group 
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manifested moderate weight loss (~9%) and lung viral loads (103.8 EID50/ml), which was 100 folds 
higher than hetero boost with H3N2 M2e. The attPR8/attPR8 and attPR8/H3N2 groups did not 
induce M2e specific IgG antibodies, and they showed more weight loss and higher lung viral 
titers, 105.2 EID50/ml and 104.3 EID50/ml respectively than 4xM2e-HA chimeric viruses (Figs. 25B, 
C), correlating the protective efficacy with M2e immunity. Hetero vaccination with attPR8 
M2e/H3N2 M2e prevented severe weight loss and reduced viral loads in 14 months old mice by 
the time of challenge with rgH5N1 virus (Figure 26). 
Consistent with the levels of lung viral titers, hetero prime boost attPR8 M2e/H3N2 M2e 
vaccination protected against lung inflammation as shown by the lowest levels of inflammatory 
cytokine IL-6 in bronchoalveolar lavage fluid (BALF) and lung at day 4 after rgH5N1 infection 
(Figure 25D). The homologous prime-boost attPR8 M2e/attPR8 M2e and attPR8/H3N2 groups 
showed high levels of inflammatory IL-6 in lung while low levels in BALF (Figure 25D). The homo 
prime boost attPR8/attPR8 group with least protection showed higher IL-6 levels in BALF and 
lung than other more protective vaccine groups. 
We also determined whether rapid induction of mucosal IgG antibodies specific for M2e 
and HA stalk domains would correlate with heterosubtypic cross protection against rgH5N1 virus 
(Figure 25E). The attPR8 M2e/H3N2 M2e group showed the highest levels of lung IgG antibodies 
specific for M2e and M2e-H1 stalk domains at day 4 after rgH5N1 challenge in young adult mice 
(Figure 25E). which was 2 and 7 folds higher respectively than those in 14 months old mice (Figure 
26C). In contrast, attPR8/attPR8 and attPR8/H3N2 groups induced M2e and HA stalk IgG 
antibodies at non-detectable levels, similar to naïve mice after infection (Figure 25E). Three to 
four folds lower levels of lung IgG antibodies for M2e and HA stalk antibodies were observed in 
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the homo attPR8 4xM2e/attPR8 4xM2e group than those in the hetero prime boost attPR8 
M2e/H3N2 M2e group (Figure 25E). Taken together, these results indicate the effectiveness of 
heterologous prime-boost vaccination in conferring cross protection against rgH5N1 virus. 
 
Figure 25 Hetero boost immunization with 4xM2e-HA chimeric virus enhances cross 
protection against A/Viet rgH5N1 virus 
C57BL/6J mice were challenged with A/Viet rgH5N1 virus (reassortant A/PR8-A/Vietnam/1203/2004, 10 
LD50, 1.6 x 106 EID50). (A) Body weight changes after challenge in young adult mice (n = 5/group). Group 
labels are the same as in the Figure 20 legend. (B-E) Young adult mice (n = 4/group) were intranasally 
prime boost immunized with attPR8/attPR8, attPR8/H3N2, attPR8 M2e/attPR8 M2e, and attPR8 
M2e/H3N2 M2e (n = 5/group) and then challenged with A/Viet rgH5N1 virus. (B) Body weight changes for 
4 days after challenge until mice were sacrificed. (C) Virus titers in lung lysates at 4 days after A/Viet 
challenge. (D) Inflammatory cytokine IL-6 levels in BALF or lung lysates day 4 post challenge with rgH5N1. 
(E) IgG antibodies specific for M2e and M2e-H1 stalk (HA2 aa1-117 from A/PR8) in lung lysates day 4 post 
challenge. Error bars indicate mean ± SEM. The statistical significances were determined using one-way 




Figure 26 Heterosubtypic attPR8 M2e prime H3N2 M2 boost intranasal vaccination 
protects one-year-old C57BL/6J mice against A/Viet rgH5N1 virus challenge 
Mice (n = 5, 1-year-old) were sequentially immunized with attPR8 M2e (5x105 EID50, 1.6 x 106 EID50) and 
H3N2 M2e (106 EID50) with 3weeks interval prior to A/Viet rgH5N1 challenge (10 LD50). (A) Body weight 
changes after A/Viet rgH5N1 virus challenge for 4 days until mice were sacrificed. (B) Lung virus titers at 
4 days after challenge. (C) Lung IgG antibodies specific for M2e or chimeric M2e-H1 stalk (HA2 aa1-117 
from A/PR8) at day 4 after A/Viet rgH5N1 virus challenge. Naïve mouse group infected with A/Viet rgH5N1 
virus is from Figure25 young naïve mice. Each individual mouse was analyzed. Error bars indicate mean ± 
SEM. The statistical significances were determined using one-way ANOVA and indicated in **, P < 0.01. 
 
3.4.5 Hetero boost in H3N2-primed mice with attPR8 M2e virus effectively induce M2e 
IgG antibodies 
Conversely, we determine the impact of hetero boost in H3N2-primed mice by comparing 
the following three prime-boost combinations, H3N2/H3N2, H3N2/attPR8, and H3N2 
M2e/attPR8 M2e (Figure 27A). Significantly enhanced levels of IgG antibodies specific for M2e 
were induced in the hetero boost H3N2 M2e/attPR8 M2e group (Figure 27B) compared to prime 
dose of H3N2 M2e (Figure 28). Similar levels of IgG antibodies specific to homologous and 
heterosubtypic viruses such as A/PR8 (H1N1), A/SW (H3N2), and A/Phil (H3N2) were detected in 
all prime-boost immunized mouse groups (Figs. 27C-E).  
Consensus group 1 stalk specific IgG antibodies were induced to a moderate level in the 
H3N2 M2e/attPR8 M2e group but not in the H3N2/attPR8 group (Figure 27F). IgG antibodies to 
consensus group 2 stalk were induced at the highest levels in the homo prime-boost H3N2/H3N2 
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group and substantial levels of consensus group 2 stalk IgG antibodies were similarly observed in 
the hetero prime-boost H3N2/attPR8 and H3N2 M2e/attPR8 M2e groups (Figure 27G).  
Homologous strain (H3N2) specific HAI titers were induced at protective levels (~128) by 
prime dose of H3N2 or H3N2 4xM2e (Figure 27H). HAI titers against H3N2 virus were further 
enhanced by 4 folds by homo boost H3N2/H3N2 vaccination (Figs. 27H, I). Heterosubtypic attPR8 
or attPR8 M2e boost immunization (H3N2/attPR8 and H3N2 M2e/attPR8 M2e) retained HAI 
titers induced by prime H3N2 dose (Figure 27H, I). Induction of HAI titers against A/PR8 might 
have been suppressed in H3N2 primed mice after attPR8 boost (Figure 27I). No HAI responses 
were observed against A/Phil from all groups (Figure 27I). 
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Figure 27 Intranasal heterosubtypic boost with chimeric 4xM2e-HA A/PR8 virus 
enhances M2e IgG responses in H3N2 primed mice 
(A) Timeline for a reverse order of H3N2 prime and H1N1 boost vaccination strategy. Mice (n = 5/group) 
were intranasally inoculated in prime-boost regimens with H3N2/H3N2, H3N2/attPR8 or H3N2 
M2e/attPR8 M2e (prime dose: 5x105 EID50, boost dose: 106 EID50) and immune sera were collected at 3 
weeks after boost. IgG antibody responses to M2e (B), A/PR8 virus (C), A/SW H3N2 virus (D), A/Phil H3N2 
virus (E), consensus group 1 stalk protein (F) and consensus group 2 stalk protein (G). HAI titers against 
influenza viruses were measured from immune sera after prime (H) and prime-boost (I) immunization. 




Figure 28 IgG antibodies specific for M2e, viruses, and HA stalk domains after prime 
vaccination with H3N2 or H3N2 M2e  
Mouse sera were collected 2 weeks after intranasal single dose (5x105 EID50) inoculation of H3N2 or H3N2 
M2e. Total IgG antibodies specific for M2e (A), A/PR8 virus (B), H3N2 virus (C), A/Phil virus (D), consensus 
group 1 stalk protein (E) and consensus group 2 stalk protein (F). Each individual mouse sera were 
analyzed. Error bars indicate mean ± SEM. The statistical significances were determined using two-way 
ANOVA and indicated in **, P < 0.01; ***, P < 0.001. 
3.4.6 Hetero boost vaccination in H3N2-primed mice induces effective protection 
against heterologous H3N2 virus 
We evaluated whether heterosubtypic boost in H3N2 primed mice would be more 
effective in inducing cross-protection against A/Phil H3N2 virus challenge (Figure 29). The hetero 
prime-boost H3N2/attPR8 and H3N2 M2e/attPR8 M2e groups displayed only ~ 4% weight loss 
and then all mice recovered (Figure 29A). In contrast, the homo prime-boost H3N2/H3N2 group 
showed approximately 10% weight loss at day 2 after A/Phil infection before recovering weight 
to a normal level (Figure 29A). Naïve mice continued to display weight loss after A/Phil virus 
infection until day 5; at this point all mice were sacrificed to collect lung tissues for viral titration. 
Reduced lung virus titers were detected in the hetero prime-boost H3N2 M2e/attPR8 M2e group 
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after A/Phil challenge, which were ~10 folds lower than those of the homo or hetero prime-boost 
H3N2/H3N2 and H3N2/attPR8 groups and approximately 105 folds lower than those in naïve mice 
with infection (Figure 29B). Significantly higher levels of IgG antibodies specific for M2e, M2e-H1 
stalk, and M2e-H3 stalk were measured in lung lysates from the hetero prime-boost H3N2 
M2e/attPR8 M2e group (Figure 29C), likely correlating with lowest lung viral titers (Figure 29B). 
Despite the highest levels of group 2 stalk specific IgG responses (Figure 27G), the H3N2/H3N2 
group did not show enhanced cross-protection against A/Phil virus (H3N2) (Figs. 29A, B). 
 
 
Figure 29 H3N2 M2e/attPR8 M2e prime-boost vaccination provides effective lung viral 
control after heterologous A/Phil H3N2 virus challenge  
The groups (n = 5/group) of mice immunized with H3N2/H3N2, H3N2/attPR8 or H3N2 M2e/attPR8 M2e 
were challenged with A/Phil virus (100x LD50, 1.4 x104 EID50). (A) Body weight changes after A/Phil H3N2 
virus challenge for 5 days until mice were sacrificed. (B) Lung virus titers at day 5 after A/Phil virus 
challenge. (C) Lung IgG antibodies specific for M2e, chimeric M2e-H1 stalk (HA2 aa1-117 from A/PR8), and 
chimeric M2e-H3 stalk (HA2 aa1-117 from A/Aichi/1968 H3N2). Each individual animal is analyzed. Error 
bars indicate mean ± SEM. The statistical significances were determined using one-way (B) or two-way (C) 





Clinical data suggest that repeat seasonal influenza vaccination might not be highly 
effective in inducing protective antibody responses (McLean et al., 2014, Thompson et al., 2016, 
Leung et al., 2017, Morimoto and Takeishi, 2018, Song et al., 2020) or lead to substantial 
heterogeneity in vaccine effectiveness (Belongia et al., 2017). Our previous studies showed that 
homologous prime-boost with A/PR8 4xM2e-HA or prime dose of attenuated rgH3N2 4xM2e-HA 
virus vaccination could be more effective in conferring broader cross-protection in BALB/c mice 
than the wild type HA counterpart virus (Kim et al., 2017a, Park et al., 2021). .  Accordingly, we 
determine whether heterologous prime-boost vaccination with recombinant influenza viruses 
containing chimeric 4xM2e-HA would induce more effective cross-protection in different genetic 
background C57BL/6 mice known to be less responsive to influenza vaccination than BALB/c mice 
(Petrovic et al., 2018). We found that heterosubtypic prime-boost provided more effective in 
conferring cross-protection than homologous vaccination. Hetero prime-boost with recombinant 
influenza viruses containing 4xM2e-HA induced high levels of IgG antibodies specific for M2e and 
reduced lung viral loads more effectively after heterosubtypic or heterologous virus challenge.  
Prime dose vaccination induced low levels of IgG antibodies for M2e and HA stalk epitopes 
in 4xM2e-HA chimeric virus, suggesting their immune-subdominance (Figure 21). Boost exposure 
to antigenically more distant chimeric virus H3N2 4xM2e-HA effectively generated M2e specific 
IgG antibodies. In the attenuated A/PR8 H1N1 (4xM2e-HA) prime and antigenically different virus 
boost groups, the levels of M2e antibodies were correlated with lowering lung viral titers and 
inflammatory cytokine (IL-6) against rgH5N1 virus challenge. The contribution of M2e antibodies 
to lowering lung viral loads was also observed in the attenuated H3N2 4xM2e-HA/PR8 4xM2e-
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HA group after A/Phil (H3N2) challenge. Importantly, Cal-head 4xM2e-HA boost induced higher 
levels of IgG binding to group 1 stalk proteins; the group 1 stalk IgG antibody levels were likely 
correlated with prevention against severe weight loss against rgH5N1 virus challenge as shown 
by the PR8-4xM2e/Cal-head 4xM2e group. These immunologic outcomes were consistent with 
the chimeric HA based vaccination strategy where multiple vaccinations were administered with 
heterosubtypic modified HA-head domains (Krammer et al., 2013, Hai et al., 2012). Consistently, 
a prior study demonstrating heterosubtypic immunity by sequential vaccination with live 
attenuated chimeric HA head-switched viruses in ferrets (Liu et al., 2019). The correlative 
contribution of M2e specific IgG antibodies to lowering lung viral loads was also observed in the 
attenuated H3N2 4xM2e-HA/PR8 4xM2e-HA group after A/Phil (H3N2) challenge. Thus, in the 
attenuated A/PR8 H1N1 prime and antigenically different boost groups, the combined M2e and 
HA stalk specific IgG levels might have contributed to cross-protection against weight loss and to 
clearing lung viral loads. Fc receptors (FcR) are known to be required for mediating protection by 
M2e and HA stalk specific antibodies (El Bakkouri et al., 2011, Kim et al., 2013a, DiLillo et al., 
2016, DiLillo et al., 2014), suggesting a significant role of antibody-dependent cell-mediated 
cytotoxicity (ADCC) in conferring protection. Not only natural killer cells from human donors 
(FcγRIIIA+primary NK) but also FcγRIIIA engineered NK-92 cells and FcγRIIIA/NFAT-RE/luc2 
engineered Jurkat T cells have been used as effector cells in bioassay evaluation of ADCC (Hsieh 
et al., 2017). We demonstrated that immune sera from the H3N2 4xM2e-HA/PR8 4xM2e-HA 
group were found to activate FcR in Jurkat cells via the target MDCK cells infected with A/Phil 
H3N2 or A/Viet rgH5N1 viruses, supporting a possible role of ADCC in mediating protection 
(Figure 30).  
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Figure 30 Heterosubtypic sequential immunization with recombinant influenza A 
viruses carrying 4xM2e-HA induces ADCC activity  
Mouse immune sera (n = 5) were collected 2 weeks after prime-boost immunization with H3N2/H3N2, 
H3N2/attPR8 and H3N2 M2e/attPR8 M2e and used to incubate on the MDCK cells infected with different 
influenza viruses before co-culturing with effector Jurkat cells. Luminescence as indicative of ADCC 
activities in each immune sera stimulating effector Jurkat cells via target MDCK cells infected with A/Phil 
H3N2 (A) and A/Viet rgH5N1 (B) virus; presented as fold changes. Pooled mouse sera in triplicates were 
analyzed. Error bars indicate mean ± SEM. The statistical significances were determined using two-way 
ANOVA and indicated in **, P < 0.01; ***, P < 0.001. 
 
Repeat vaccination was shown to induce lower antibody titers than current seasonal 
vaccination only (Thompson et al., 2016, Sanyal et al., 2019, Leung et al., 2017) and might lead to 
reduced antibody-affinity maturation (Khurana et al., 2019). In addition, repeated homologous 
vaccination was less effective in protection against H3N2 virus than single vaccination in ferrets 
despite no significant differences in antibody levels (Music et al., 2019). It should be noted that 
compared to the heterosubtypic H3N2/H1N1 (A/PR8) vaccination, prime-boost with H3N2 virus 
(2013 isolate) resulted in more weight loss against A/Phil virus (1982 isolate) at days 2 to 3 post 
challenge, while it induced higher levels of homologous HAI titers and IgG antibodies for group 2 
stalk protein and similar outcomes in lung viral loads. Similarly, higher levels of group 1 stalk IgG 
antibodies induced by attenuated PR8/PR8 prime-boost did not improve cross-protection against 
rgH5N1 virus compared to the PR8/H3N2 group, which induced near background levels of group 
1 stalk specific antibodies. High levels of anti-HA stalk antibodies were reported in the elderly 
individuals (Nachbagauer et al., 2016), in which population influenza-related morbidity and 
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mortality are mostly associated. Thus, caution should be given in correlating HA stalk specific 
antibody levels with cross-protection. Therefore, inducing extra M2e immunity might provide a 
safeguard, protecting from severe disease and mortality during a pandemic to which individuals 
are naïve. 
The elderly populations display poor responses to vaccination because of immuno-
senescence, limited naïve B cells and IgG repertoire (Crooke et al., 2019) ,reduced capacity to 
target antigenically distinct epitopes, and less somatic hypermutations (Henry et al., 2019). One 
year old C57BL/6 mice were less effective compared to young adult mice in inducing HAI titers, 
IgG antibodies to M2e and particularly to HA stalk domain. They were also poorly responsive to 
boost dose in the PR8 4xM2e/H3N2 4xM2e group. To overcome poor responses to low 
immunogenic but conserved epitopes, immunizing younger age populations with vaccines 
targeting M2e and HA stalk proteins would be an approach for future studies.  
A strategy of heterosubtypic prime-boost with vaccines inducing strain specific HAI titers 
and IgG antibody responses to conserved M2e and HA stalk domains would improve the breadth 
of cross-protection. In the attenuated A/PR8 prime set with A/SW H3N2 boost, HAI titers against 
both vaccine strains were induced without significant compromise. However, in the reverse 
A/SW H3N2 prime and attenuated A/PR8 boost, HAI responses to A/PR8 were compromised 
although both strains are antigenically unrelated. This might be because attenuated A/PR8 
viruses would not replicate at sufficient levels under pre-existing immunity against A/SW H3N2 
virus whereas A/SW H3N2 virus could replicate both in the upper and lower respiratory tracts 
(Figure 19C). Hence, further studies will be needed to better understand heterosubtypic prime-
boost strategies.  One caveat of this study is that live attenuated influenza vaccines are not 
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generally recommended in adults and elderly populations probably due to pre-existing immunity 
negatively affecting vaccine effectiveness. Live attenuated vaccine platforms of head-domain 
switched chimeric HA-based universal influenza virus vaccine candidates were not effective 
inducing anti-H1 stalk IgG responses whereas AS03-adjuvanted inactivated virus vaccines were 
immunogenic in raising durable HA stalk specific antibodies at several folds higher levels in phase 
1 studies (Bernstein et al., 2020, Nachbagauer et al., 2021). Inactivated virus platforms of 
recombinant virus vaccines with 4xM2e-HA were not effective in inducing M2e specific IgG 
antibody responses after intramuscular immunization of mice (data not shown). In contrast, 
previous studies reported alternative strategies of recombinant influenza viruses where the 
foreign epitopes (M2e, conserved NA or neutralizing epitopes of respiratory syncytial virus fusion 
protein) were inserted in the immunodominant HA head domain, which induced epitope specific 
antibodies after vaccination of mice with inactivated vaccine platforms and conferred improved 
protection against challenge with antigenically different viruses (Kim et al., 2020, Lee et al., 2016). 
A universal vaccine that effectively induces both protective M2e and HA stalk immune responses 
remains to be developed. 
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4 HEMAGGLUTININ VIRUS-LIKE PARTICLE IS IMMUNOGENIC AND PROVIDES HETEROLOGOUS 
PROTECTION AGAINST INFLUENZA VIRUS IN YOUNG ADULT AND AGED MICE 
4.1 Abstract 
Immunosenescence and weak responses to vaccination result in high mortality and 
morbidity of influenza in elderly population. In this study, we investigated the immunogenicity 
and cross-protection of virus-like particle containing hemagglutinin from A/Puerto Rico/8/1934 
H1N1 (PR8 HA VLP) in 18 months old (aged) mice in comparison with those in young adult mice. 
PR8 HA VLP vaccination induced homologous and cross-reactive IgG antibodies to A/PR8, 
A/WSN/1933 (H1N1), and A/California/2009 (H1N1) in young adult and aged mice. Lower IgG 
responses specific for heterologous virus and HA stalk protein antigens and hemagglutination 
inhibition titers were induced in aged mice in a dose dependent pattern. Young adult mice with 
PR8 HA VLP vaccination conferred higher efficacy of homologous protection against A/PR8 and 
heterologous protection against A/WSN than old age mice. Also, cross-protection against 
antigenically distinct A/California/2009 was observed in young adult mice but not in aged mice 
after PR8 HA VLP immunization and challenge. Higher doses of PR8 HA VLP were required for 
protection in aged mice. Efficacy of controlling lung viral replication against A/PR8 and A/WSN 
was significantly enhanced in aged mice by incorporation of cytokine-adjuvants (GM-CSF and IL-
12) into PR8 HA VLP via protein transfer in vitro. Effects of cytokines incorporated onto HA VLP 
were substantial on inducing IFN-γ+ CD4 and CD8 T cell responses in young adult and aged mice. 
Induction of IgG antibodies and cross-protection by PR8 HA VLP vaccination was comparable in 
male and female mice. These results suggest that VLP-based influenza vaccine is immunogenic in 
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young and old age mice and a strategy of cytokine-adjuvanted HA VLP vaccination might provide 
more protective benefits in elderly population. 
4.2 Introduction 
Influenza viruses belong to the Orthomyxoviridae and consist of eight segmented 
negative-sense single-stranded RNAs (Krammer et al., 2018b). Influenza A viruses are a highly 
transmissible agent responsible for human respiratory illness annually and causing pandemics 
(Harrington et al., 2021). CDC estimates that 70-85 percent of seasonal flu-related deaths occur 
among the people 65 years and older.  Effective vaccination has been proven to be the most 
effective measure to prevent infectious diseases. However, vaccine effectiveness in the elderly 
population is lower compared to young adult age groups (Rondy et al., 2017). This phenomenon 
of low responses to vaccination is mainly due to their weakened immune system which is 
described as immunosenescence and partially due to prior influenza exposure and original 
antigenic sin (Tanner et al., 2021, Hodgins et al., 2019). Currently, a high dose influenza vaccine 
and an adjuvanted vaccine were approved in the U.S. for the people 65 years and older (CDC, 
2021d, CDC, 2021a). These enhanced influenza vaccines induce elevated hemagglutination 
inhibition (HAI) titers by improved immunogenicity of vaccines (CDC, 2021c). 
Virus-like particles (VLPs) are self-assembled nanoparticles (20-200 µm) that closely 
resembles the structure of virus in sizes and shapes but lacking viral genomes (Kang et al., 2012). 
The nanosized VLPs are allowed to traffic into lymph nodes and enable uptake by antigen-
presenting cells (APCs) (Cubas et al., 2009). VLPs are immunogenic and induce both humoral and 
cellular anti-viral immune responses (Crisci et al., 2012). VLPs can be generated to display diverse 
antigenic epitopes (Frietze et al., 2016). Vaccination of ferrets with VLPs containing influenza 
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hemagglutinin (HA) from A/California/2009 was shown to induce more protective immunity than 
conventional inactivated virus vaccination (Hossain et al., 2011). These features represent VLP as 
a potent and safe vaccine platform especially for older adults and immunocompromised people. 
Expressing immunostimulatory molecules (ISMs) in VLPs would be an effective strategy to 
improve the immunogenicity of influenza VLPs, thus developing broader cross-protection (Kang 
et al., 2012). 
Granulocyte macrophage colony-stimulating factor (GM-CSF) and Interleukin-12 (IL-12) 
as endogenous immune activators were reported to enhance the immunogenicity of vaccines for 
Ebola, SARS-CoV-2, influenza viruses and tumor in a mouse model (Eager and Nemunaitis, 2005, 
Herbert et al., 2009, Suschak et al., 2018, Vernet et al., 2021). To deliver these immune activators, 
VLPs can be genetically modified to express GM-CSF and IL-12. However, this method of genetic 
approaches applied multiple recombinant baculovirus (rBV) infection to display diverse 
molecules and was not highly effective in enhancing immune responses to vaccine antigens 
(Skountzou et al., 2007).  
Previous studies have shown in vitro incorporation into the VLP lipid membranes of ISMs 
such as B7-1, IL-12. ICAM-1 or GM-CSF via membrane-anchoring phosphatidylinositol (GPI) 
conjugates using protein transfer technology (McHugh et al., 1999, Nagarajan and Selvaraj, 2002, 
Poloso et al., 2002, Patel et al., 2015b), which resulted in enhancing antitumor immune 
responses. Also, incorporation of GPI anchored GM-CSF to VLPs was reported to improve anti-
viral immunity after vaccination of young adult mice (Patel et al., 2015a). 
Here, influenza VLP vaccines that express HA from A/PR8 (PR8 HA VLP) were modified to 
display GPI anchored GM-CSF and GPI-IL-12 on the VLP surface via protein transfer. The goal of 
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this study was to determine whether influenza VLP vaccines with cytokines incorporated would 
enhance protective humoral and cellular immunity in aged mice, compared to those in young 
adult mice. Aged mice required higher doses of influenza VLP vaccine to induce protective 
immune responses than young adult mice. PR8 HA VLP (PR8 HA-Cy VLP) displaying cytokines (GM-
CSF and IL-12) was conferred improved protection against homologous and heterologous 
influenza viruses in aged mice. PR8 HA-Cy VLP was more effective in inducing cellular immune 
responses although the impact of cytokine incorporation into VLP on protection was not 
significant in young adult mice.  This study demonstrates a strategy of improving protection by 
adjuvantation of influenza VLP vaccines with GM-CSF and IL-12 immune activators in young adult 
and aged mouse models. 
4.3 Materials and Methods 
4.3.1 Preparation of influenza virus-like particles (VLPs) 
VLP expressing HA protein from A/PR/8/1934 H1N1 virus (PR8 HA VLP) was prepared by 
Medigen, Inc. (Frederick, MD) and incorporation of cytokines including GM-CSF and IL-12 on to 
PR8 HA VLP (PR8 HA-Cy VLP) was performed by Metaclipse Therapeutics Corporation (Atlanta, 
GA). In brief, a gene encoding HA (A/PR/8/1934) was codon-optimized for expression in insect 
cells and cloned into pFastbac plasmid vector with influenza M1 gene for dual expression 
(M1+HA). Recombinant baculovirus (rBV) expressing M1 and HA was generated in insect cells by 
using the Bac-to-Bac expression system and transfection with M1+HA pFastbac bacmid DNA as 
previously described (Pushko et al., 2017, Tretyakova et al., 2016, Tretyakova et al., 2013).   PR8 
HA VLP was produced in Sf9 insect cells after infection with rBV expressing HA and M1. Soluble 
cytokines were expressed and purified from CHO-K1 cells after transfection with GM-CSF or IL-
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12 expressing vectors that also contains GPI-membrane-anchoring sequence derived from CD59. 
The GPI-IL-12 construct was placed in a pUB6blast vector (Invitrogen), whereas GPI-GM-CSF 
construct was placed in a pcDNA3Neo vector (Invitrogen). Purified GPI-cytokines (GM-CSF and IL-
12) were incorporated onto PR8 HA VLP by protein transfer (HA-Cy VLP) as previously described 
(Patel et al., 2015a). Characterization of PR8 HA VLP was performed by Coomassie blue staining 
of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and incorporation of 
GM-CSF or IL-12 was determined by western blot analysis using anti-mouse GM-CSF or anti-
mouse IL-12 p40 antibodies (BioXCell) respectively. 
4.3.2 Immunization and virus challenges 
Young adult female, male (6-8 weeks old, Jackson Laboratories) and aged female (18-
month-old, NIH/NIA) BALB/c mice received sequential prime-boost intramuscular vaccination 
with PR8 HA VLP (HA VLP) or PR8 HA-Cy VLP (HA-Cy VLP with GM-CSF and IL-12 incorporated) in 
an interval of 3 weeks. Before homologous A/Puerto Rico/8/1934/H1N1 (A/PR8/34) virus 
challenge (2 LD50, 103.36 EID50), young adult female mice (n= 6/group) were prime-boost 
immunized with 1 µg of HA VLP and aged female mice (n= 5/group) were prime-boost immunized 
with 1 µg or 3 µg of HA VLP or HA-Cy VLP (Figure 36). Young female mice (n= 4/group) were 
prime-boost immunized with 1 µg or 3 µg of VLP or HA-Cy VLP prior to A/WSN/1933/H1N1 
(A/WSN/33) virus infection (2 LD50, 101.06 EID50 or 8 LD50, 101.66 EID50 respectively, Figure 37). Aged 
female mice (n= 3-6/group) were prime-boost immunized with 1 µg or 6 µg of VLP or HA-Cy VLP 
before 1.5 LD50 (8.7 EID50) of A/WSN/33 virus challenge (Figure 37). Young female mice (n= 
3/group) were prime-boost immunized with 6 µg of VLP or HA-Cy VLP prior to 
A/California/04/2009/H1N1 (A/Cal/09) virus infection (Figure 39). Young male mice (n= 3/group) 
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were prime-boost immunized with 1 µg of VLP or HA-Cy VLP prior to infection by 8 LD50 (8.7 EID50) 
of A/WSN/33 virus or 2 LD50 (103.6 EID50) of A/Cal/09 virus (Figure 41). All animal experiments in 
this study were approved by the Georgia State University Institutional Animal Care and Use 
Committee (IACUC) review boards. Mouse animal experiments including virus infection, blood 
and tissue collections were performed in accordance with the approved IACUC protocol (A21004) 
and regulations. 
4.3.3 Enzyme linked immunosorbent assay (ELISA) 
IgG antibodies specific for the viruses were measured by ELISA with coating antigens (4 
μg/ml) from inactivated A/PR8/34, A/WSN/33, A/Cal/09 H1N1 and A/Viet rgH5N1 viruses. 
A/PR8/34 specific IgG isotypes (IgG1 and IgG2a) were measured. HA stalk specific IgG antibodies 
were determined using consensus group 1 HA stalk protein as coating antigens constructed and 
prepared as previously reported (Chae et al., 2019). HRP (Horseradish Peroxidase) conjugated 
goat anti-mouse IgG, IG1, ang IgG2a (southern Biotechnology) were used as a secondary 
antibody. 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Invitrogen™) was utilized for color 
development. IgG antibody levels were read by BioTek ELISA plate reader at 450nm. 
4.3.4 Hemagglutination inhibition (HAI) titers 
Mouse prime-boost immunized sera were treated with receptor destroying enzymes 
(RDE, Sigma) with 1:3 ratio and incubated at 37 °C overnight and inactivated at 56°C for 30 
minutes. RDE-treated serum samples were serially diluted (two-fold) and treated with the equal 
volume of viruses (4 hemagglutination activity units). HAI titers were measured as the highest 
dilution factor inhibiting the formation of buttons with 0.5% chicken red blood cells (RBC). 
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4.3.5 Assays of lung viral titers and inflammatory cytokines 
Lung lysates were obtained day 5 - 9 post infection from the lung homogenates in 1.5ml 
of RPMI media after centrifugation. Virus titers were determined by calculating 50% egg 
infectious dose (EID50) after incubation at 37ºC for 3 days in the 10-day-old embryonated chicken 
eggs. Cytokine interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interferon gamma 
(IFN-γ) ELISA was performed as described previously using Ready-Set-Go kits (eBioscience, San 
Diego, CA). 
4.3.6 Intracellular cytokine staining of T cells 
Lung cells were stimulated with inactivated A/PR8/33 (4 µg/ml) or A/PR8 HA peptides 
(CD4+ epitopes (2.5 µg/ml each peptide): SFERFEIFPKE, HNTNGVTAACSH, CPKYVRSAKLRM, 
KLKNSYVNKKGK, NAYVSVVTSNYNRRF, CD8+ epitopes (5 µg/ml each peptide): LYEKVKSQL, 
IYSTVASSL)) for 5 h at 37 °C in the presence of brefeldin A (BFA) (20 μg/mL). After stimulation, 
lymphocytes were stained with T cell marker antibodies for CD4 (CD4-PE/Cy5, BD Biosciences) 
and CD8 (CD8α-PE, Biolegend) by following a procedure of BD Cytofix/Cytoperm Plus Kit. 
Intracellular staining of the permeabilized lymphocytes was conducted with IFN-γ cytokine mAb 
(anti-mouse IFN-γ-APC/Cy7, BD Biosciences). All samples were analyzed by using LSR-II/Fortessa 
flow cytometer (BD Biosciences, San Diego, CA, USA) and analyzed using the FlowJo software 
(FlowJo V10, Tree Star, Inc.). 
4.3.7 Statistical analysis 
Two-way or one-way ANOVA were used to determine the statistical significance when 
comparing two different conditions. P-values of less than or equal to 0.05 were considered 
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significant. Data analysis was performed using Prism software (GraphPad software Inc., San 
Diego, CA). 
4.4 Results 
4.4.1 PR8 HA VLP and PR8 HA-Cy vaccines are immunogenic in aged mice at a 
higher dose compared to young adult mice 
To enhance the immunogenicity, endogenous immune activators (cytokines) such as 
granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) were 
incorporated into PR8 HA VLP via a glycosylated phosphatidylinositol (GPI) anchor (Prepared by 
Medigen, Inc. (Frederick, MD) and Metaclipse Therapeutics Corporation (Atlanta, GA) as in 
described in materials and methods section, Figure 31A) (Patel et al., 2015a). A/PR8 
hemagglutinin (HA) H1 and matrix M1 proteins from PR8 HA VLP expressed and purified from 
insect cells were characterized by SDS-PAGE and Coomassie blue staining (Figure 31B), indicating 
the high purity and major components HA and M1. The incorporated cytokines were confirmed 
by western blot analysis with anti-GM-CSF and anti-IL-12 antibodies (Figure 31C). 
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Figure 31 Preparation of PR8 HA VLP and PR8 HA-Cy VLP vaccines 
(A) Schematic diagram of protein transfer of GPI-anchored cytokines (GM-CSF and IL-12) onto PR8 HA VLP. 
(B) SDS-PAGE gel staining of PR8 HA VLP expressed in insect cells after purification, displaying HA and M1 
proteins as major components. (C) Western blot analysis of incorporated GM-CSF or IL-12 in PR8 HA VLPs 
using anti-mouse GM-CSF antibody and anti-mouse IL-12 p40 antibody respectively. [Define PR8 HA VLP 
and PR8 HA-Cy VLP here]PR8 HA VLP: Virus-like particle (VLP) that expresses HA from A/PR8/34, PR8 HA-
Cy VLP: PR8 HA VLP incorporated with GM-CSF and IL-12. 
 
Here we focused on investigating the homologous immunogenicity and efficacy of 
A/PR8/1934 (H1N1) HA VLP (HA VLP) and PR8 HA VLP incorporated with GM-CSF and IL-12 (HA-
Cy VLP) in old aged BALB/c mice (16-18 months old age) in comparison with those in young adult 
BALB/c mice. Young adult (6-8 weeks old, Figs. 32A-C) and aged (16 – 18 months old, Figs. 32D-
F) BALB/c mice were intramuscularly immunized with HA VLP or HA-Cy VLP at different doses (1, 
3 or 6 µg, respectively in Figure 32). After low dose (1µg) prime vaccination of each VLP, young 
adult mice induced higher levels of A/PR8 specific IgG antibody response compared to those in 
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aged mice (Figs. 32A, D). With increasing the HA VLP and HA-Cy VLP vaccine dose to a moderate 
(3µg) to high (6µg) level, the aged mouse groups after prime vaccination induced substantially 
higher responses of IgG antibodies specific for homologous A/PR8 virus despite slightly lower 
than those in young adult mice (Figs. 32B, C, E, F). Boost immunization effects on enhancing IgG 
antibody responses were most prominent with 1 µg of HA VLP or HA-Cy VLP primed young adult 
age and elderly aged mice (Figs. 32A, D). Boost immunization with 3µg or 6µg of both HA VLP and 
HA-Cy VLP resulted in moderate increases in IgG levels specific for A/PR8 virus, where IgG levels 
in young adult mice (Figs. 32B, C) were still significantly higher than those in aged mice (Figs. 32E, 
F). There were more prominently lower levels of IgG2a isotypes in aged mice (Figs. 33E, H) than 
those in young adult mice (Figs. 33B, D) although both IgG1 and IgG2a antibodies were lower in 
aged mice (Figs. 33E-H).  Moderate to high doses of HA-Cy VLP (3 or 6 µg) immunization induced 
slightly increased IgG1 antibody responses to A/PR8 compared to HA VLP inoculation in both 
young and aged mice (Figs. 33A, C, E, G). These results suggest that HA VLP and HA-Cy VLP 
effectively primed the induction of A/PR8 specific IgG antibodies in aged mice in a dose 
dependent manner. The capacity to induce IgG antibodies to low dose HA VLP or HA-Cy VLP prime 




Figure 32 Intramuscular immunization of PR8 HA VLP and PR8 HA-Cy VLP induces IgG 
antibodies specific for homologous A/PR8 virus in young and aged mice 
Young adult and aged BALB/c mice (n= 6/group) were immunized with 1 µg (A, D), 3 µg (B, E) or 6 µg (C, 
F) of HA VLP (HA) or HA-Cy VLP (HA-Cy). Mouse sera were collected at 2 weeks after prime or boost 
immunization. IgG antibody responses to A/PR8 virus were measured in prime (p) or boost (b) immune 
sera. Each individual mouse is analyzed. Error bars indicate mean ± SEM. 
 
 
Figure 33 A/PR8 specific serum IgG isotype antibody responses after boost dose of PR8 
HA VLP or PR8 HA-Cy VLP 
Young adult (A-D) and aged (E-H) BALB/c mice (n= 6/group) were received boost dose of HA VLP (HA) or 
HA-Cy VLP (HA-Cy). IgG1 and IgG2a antibody responses to A/PR8 2 weeks after 3 µg (A, B, E, F) or 6 µg (C, 
D, G, H) of each VLP inoculation. Each individual mouse is analyzed. Error bars indicate mean ± SEM. 
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4.4.2 Aged mice induce low levels of cross-reactive IgG antibody responses after 
HA VLP or HA-Cy VLP vaccination 
Sera of boost immunization with HA VLP or HA-Cy VLP were analyzed for cross reactivity 
against heterologous viruses, A/WSN/1934 (H1N1) and A/California/2009 (H1N1) in young 
(Figure 34A-G) and aged mice (Figure 34H-M). Boost sera from aged mice displayed significantly 
lower levels (~3 folds) of IgG antibodies specific for A/WSN/1934 (H1N1) (Figure 34H, K) and 
A/California/2009 (H1N1) (Figure 34I, L) than those from young adult mice after immunization 
with 3 µg (Figure 34A-C, H-J) or 6 µg (Figure 34E-G, K-M) of each VLP (Figure 34A, B and Figure 
34E, F respectively). With a higher dose (6 µg) of HA VLP or HA-Cy VLP boost sera from young 
adult and aged mice showed increased levels of IgG antibody reactivity to A/WSN (Figure 34E, K) 
than with a 3 µg each VLP (Figure 34A, H). We observed a similar pattern of cross-reactive IgG 
antibodies recognizing A/California/2009 (H1N1) but at significantly lower levels than those 
recognizing A/WSN in both young adult and elderly aged mice, probably due to antigenic distance 
(Figure 34B, F, I, L). Approximately 2-fold higher IgG antibodies to group 1 stalk were induced 
from young adult mice than aged mice after boost dose (both 3 and 6 µg) of HA VLP or HA-Cy VLP 
(Figure 34C, G compared to Figure 34J, M). These results suggest that elderly aged mice have 
more limited capacity to induce cross reactive IgG antibody responses to heterologous viruses 
than young adult mice. 
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Figure 34  IgG antibody reactivities to A/WSN, A/Cal and group 1 stalk domain induced 
by vaccination with PR8 HA VLP or PR8 HA-Cy VLP in young and aged mice 
Immune sera were collected at 2 weeks after boost immunization with HA VLP or HA-Cy VLP from young 
adult (A-G) and aged (H-M) Balb/c mice (n= 6/group). HA VLP (HA) or HA-Cy VLP (HA-Cy) with vaccine dose 
3 µg (A-C, H-J) or 6 µg (E-G, K-M) were inoculated intramuscularly in two doses at an interval of 3 weeks. 
IgG antibody responses to A/WSN (A, E, H, K), A/Cal (B, F, I, L), and group 1 stalk domain (C, G, J, M). Each 
individual mouse is analyzed. Error bars indicate mean ± SEM. 
 
4.4.3 HA VLP and HA-Cy VLP induces hemagglutination inhibition activity against 
homologous at higher levels in young adult than those in aged mice 
To determine hemagglutination inhibition (HAI) titers, sera from young adult and aged 
mice were collected after boost immunization with 1, 3 or 6 µg of HA VLP or HA-Cy VLP (Figure 
35). HAI activity was observed in all doses of immune sera against homologous A/PR8 but not 
against heterologous viruses including A/WSN and A/Cal. Although both age groups with HA VLP 
or HA-Cy VLP immunization showed significantly increased HAI activity than the naive group, 
young adult mice showed 20-fold higher HAI titers than aged mice after 1 µg of HA VLP or HA-Cy 
VLP immunization (Figure 35A). With higher doses of immunization (3 or 6 µg), 8-16 folds 
increased HAI titer was observed from aged mice (Figs. 35B, C). These results support that high 




Figure 35 Serum hemagglutination inhibition (HAI) titers against homologous and 
heterologous viruses  
HAI titers against the viruses (A/PR8, A/WSN, and A/Cal) were determined in sera from young adult and 
aged mice (n= 6/group) at 2 weeks after boost immunization with HA VLP or HA-Cy VLP. (A-C) 1 µg, 3 µg 
or 6 µg of each VLP were administered respectively. Each individual mouse is analyzed. The statistical 
significances were determined using two-way ANOVA and indicated in *, P < 0.1; ***, P < 0.001. Error bars 
indicate mean ± SEM. 
4.4.4 A low dose HA VLP confers homologous protection in young adult mice 
whereas higher dose HA VLP is required for protection in aged mice 
To determine the protection efficacy, young adult BALB/c mice were challenged with a 
lethal dose of A/PR8 at 3 or 4 weeks after HA VLP low dose (1 µg) boost immunization. Vaccinated 
mice did not lose body weight meanwhile the naïve group reached humane end point (20%) after 
A/PR8 challenge (Figure 36A). Also, at day 5 after A/PR8 challenge, lung virus titers were 
determined by measuring 50 % egg infectious dose (EID50) from the HA VLP vaccinated and naïve 
young adult groups (Figure 36B). No virus was detected from HA VLP young adult group in 
contrast to the naïve group displaying high lung virus titers (7.4 log10EID50/ml). Similarly, the aged 
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BALB/c mice immunized with low dose HA VLP or HA-Cy VLP (1 µg) were challenged with a lethal 
dose of A/PR8 at 4 weeks after boost. The aged mouse group with low dose of HA VLP vaccination 
showed severe weight loss (~20%) with 80% survival rates whereas HA-Cy vaccinated group lost 
less body weight (~10%) and survived at 100%. Unvaccinated mice did not survive after infection 
(Figure 36C, D). For further assessment, the aged BALB/c mouse groups that were vaccinated 
with 3-fold higher dose (3 µg) of HA VLP or HA-Cy VLP were challenged with a lethal dose of 
A/PR8. No body weight loss was observed in both HA VLP and HA-Cy groups (Figure 36E). HA VLP 
vaccination displayed lower lung virus titers (2.4 log10EID50/ml, Figure 36F) compared to the 
unvaccinated naïve group showing 1,000 folds higher titers (7.4 log10EID50/ml). Notably, no virus 
was detected from the HA-Cy VLP aged mice group (Figure 36F). All together, these results 
suggest that a lower dose HA VLP can confer homologous protection in young mice whereas 
higher dose HA VLP is required for protection in aged mice. Also, HA-Cy VLP can improve the 
protection by more effectively controlling the viral replication in the lung. 
 
Figure 36 Aged mice need a higher dose of PR8 HA-Cy VLP to induce protection against 
homologous A/PR8 virus than young adult mice 
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Young adult mice (n= 6/group, A, B) were prime-boost immunized with a low dose (1 µg) of HA VLP prior 
to A/PR8 virus infection (2 LD50, 103.36 EID50). (A) Body weight changes and (B) lung virus titer at day 5 after 
A/PR8 challenge. Aged BALB/c mice (n= 5/group) were prime-boost immunized with 1 µg (C, D) or 3 µg (E, 
F) of HA VLP or HA-Cy VLP. (C, E) Weight changes, (D) survival rate and (F) lung virus titer at day 6 after 
A/PR8 virus (2 LD50) challenge. Naïve: Naïve mice with infection. Each individual mouse is analyzed. Error 
bars indicate mean ± SEM. 
4.4.5 HA VLP or HA-Cy VLP vaccine even at low dose provides heterologous 
cross-protection against A/WSN in young adult mice 
We determined whether HA VLP or HA-Cy VLP would induce cross-protection against 
A/WSN/1933. At 3 weeks after low dose (1 µg HA VLP prime and boost vaccination), young adult 
BALB/c mice were challenged with a lethal dose of A/WSN (Figure 37A). HA VLP or HA-Cy VLP 
vaccinated mice did not lose body weight after infection while the naive control group showed 
severe body weight loss and did not survive (Figure 37A). In an additional set to further test cross-
protection, the mice vaccinated with 3 µg of prime-boost HA VLP or HA-Cy VLP were challenged 
with 4 folds higher dose of A/WSN. The HA VLP or HA-Cy VLP immune mice were well cross 
protected against A/WSN without displaying weight loss and lung virus titers were below the limit 
of detection (Figure 37B) at day 8 after challenge. In addition, lower inflammatory cytokine such 
as IL-6 was detected from the lung of vaccinated groups with HA VLP or HA-Cy VLP (3 µg) 
compared to naïve mice after A/WSN infection (Figure 38A). These results suggest that HA VLP 
or HA-Cy VLP vaccine even at low dose can provide heterologous cross-protection against A/WSN 
in young adult mice.  
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Figure 37 Aged mice require a higher dose of PR8 HA-Cy VLP to provide cross-
protection against A/WSN virus than young adult mice  
Young female adult BALB/c mice (n= 4/group) were prime-boost immunized with 1 µg (A) and 3 µg (B) of 
HA VLP or HA-Cy VLP before heterologous virus challenge. (A) Body weight changes after A/WSN infection 
(2 LD50, 101.06 EID50) in a low dose (1 µg) of each VLP vaccine groups. (B) Weight changes and lung virus 
titer at day 8 after A/WSN (8 LD50, 101.66 EID50) challenge in higher dose (3 µg) of each VLP vaccine groups. 
(C, D) Aged BALB/c (n= 3-6/group) mice received prime-boost immunization with 1 µg (C) or 6 µg (D) of 
HA VLP or HA-Cy VLP before A/WSN infection (1.5 LD50, 8.7 EID50). Body weight changes and lung virus 
titers at day 9 (D) after A/WSN (1.5 LD50, 8.7 EID50) challenge. Naïve: Naïve mice with infection. Each 
individual mouse is analyzed. Error bars indicate mean ± SEM. The statistical significances were 
determined using One-way ANOVA and Turkey's multiple comparison test and indicated in **, P < 0.01; 
***, P < 0.001. 
4.4.6 Aged mice require a higher dose HA VLP or HA-Cy VLP vaccine to induce 
heterologous cross-protection 
To determine the efficacy of cross-protection in aged BALB/c mice, HA VLP low dose (1 
µg) boosted mice were challenged with A/WSN (Figure 37C). At day 7 after challenge, all mouse 
groups including HA VLP, HA-Cy VLP and naïve lost body weight (18%, 14% and 25% loss 
respectively, Figure 37C). PR8 HA-Cy VLP immunized mice displayed approximately 100-fold 
lower lung virus titer (3.7 log10EID50/ml) than PR8 HA VLP group (6 log10EID50/ml). Both 
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immunized groups showed reduced lung virus titer compared to naive control group (8 
log10EID50/ml) at day 7 after challenge (Figure 37C). To determine the effect of higher dose 
vaccines, aged BALB/c mice prime-boost immunized with 6 µg of HA VLP or HA-Cy VLP were 
challenged with a lethal dose of A/WSN. Weight loss was not observed from the vaccinated 
groups with 6 µg of HA VLP or HA-Cy VLP while naïve mice lost 11% body weight by day 9 after 
infection (Figure 37D). Since HA VLP or HA-Cy immunized aged mice did not show weight loss, we 
determined lung viral titers. Approximately 300-fold lower lung virus titer was detected from the 
HA VLP immunized mice (3.9 log10EID50/ml) than the naïve group (6.4 log10EID50/ml) and no virus 
was detectable in HA-Cy VLP group (Figure 37D). As in young mice (Figure 38A), reduced 
inflammatory cytokines including TNF-α, IFN-γ and IL-6 were detected from the lung of 
vaccinated groups with HA VLP or HA-Cy VLP (3 µg) compared to naïve mice after A/WSN 
infection (Figure 38B). Intracellular cytokine staining data displayed significantly increased levels 
of IFN-γ secreting CD4 T cells (Figure 38C) and CD8 T cells (Figure 38D) upon stimulation with HA 
peptides or inactivated A/PR8 virus in lung cells from HA VLP or HA-Cy VLP (3 µg) boosted both 
young and aged mice compared to unvaccinated naïve mice. Moreover, elevated IFN-γ secreting 
CD4 T (Figure 38C) cells and CD8 T cells (Figure 38D) were observed in HA-Cy VLP boosted group 
compared to HA VLP vaccine group in all cases. Taken together, these results indicate that T cell 
immunity induced by HA VLP and HA-Cy VLP. Also, aged mice require a higher dose HA VLP 
vaccine to induce heterologous cross-protection against A/WSN virus and HA-Cy VLP might 
contribute on enhanced cross-protection in aged mice. 
95 
 
Figure 38 PR8 HA VLP or PR8 HA-Cy VLP vaccination reduced inflammatory cytokines 
and induced T cell responses in young and aged mice  
Inflammatory cytokines and T cell responses were determined in lung tissues collected day 5   post 
challenge from young adult and aged BALB/c mice (n= 6/group) that were prime-boost immunized with 3 
µg of HA VLP or HA-Cy VLP. (A) Inflammatory IL-6 in lung lysates from young mice after A/WSN challenge 
(8 LD50, 101.66 EID50). (B) Inflammatory cytokines TNF-α, IFN-γ and IL-6 in lung lysate from aged mice after 
A/WSN challenge (1.5 LD50, 8.7 EID50). IFN-γ-producing CD4+ T cells (C) or CD8+ T cells (D) specific for HA 
peptides and A/PR8 after intracellular staining were gated and quantified by flow cytometry from lung 
cells at day 5 after challenge by A/WSN (young adult mice: 101.66 EID50, aged mice: 8.7 EID50). Each 
individual mouse is analyzed. Error bars indicate mean ± SEM. The statistical significances were 
determined using One-way ANOVA and Turkey's multiple comparison test and indicated in *, P < 0.1; **, 
P < 0.01; ***, P < 0.001. 
4.4.7 PR8 HA VLP vaccine provides heterologous cross-protection against 
antigenically distant A/California/2009 virus in young adult mice  
To test cross-protection against an antigenically distant virus, young adult mice boosted 
with HA VLP or HA-Cy VLP (6 µg each) were challenged with a lethal dose of A/California/2009 at 
3 weeks after boost (Figure 39). The young adult HA VLP or HA-Cy VLP immune mice displayed 
100% survival rate and less weight loss (15%) than the naïve group (>25%) that did not survive 
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after A/Cal challenge. Collectively, these data suggest that HA VLP or HA-Cy VLP can provide 
survival protection against antigenically distant A/Cal in young adult mice. 
 
Figure 39 PR8 HA VLP vaccination induces survival protection against heterologous 
A/Cal virus in young mice  
(A) Body weight changes and (B) survival rate after challenge with A/Cal virus (2 LD50, 103.6 EID50) from 
young adult mice (n= 3/group) immunized with 6 µg of HA VLP or HA-Cy VLP. Each individual mouse is 
analyzed. Error bars indicate mean ± SEM. 
4.4.8 Male BALB/c mice induce comparable immune responses and cross-
protection after PR8 HA VLP vaccination 
Gender is an important biological parameter to be considered in determining the vaccine 
effectiveness. Virus specific IgG antibody responses in immune sera from young adult male 
BALB/c mice (n= 6/group) prime-boost immunized with HA VLP or HA-Cy VLP (1 µg each) were 
determined in comparison with those from young adult female BALB/c mice (Figure 40). The 
levels of A/PR8 specific IgG antibodies at 2 weeks after prime immunization (Figure 40A) and 
A/PR8 specific IgG, IgG1, or IgG2a antibody responses after boost vaccination (Figs. 40B-D 
respectively) of male mice were comparable with those of female mice. As induced in female 
mice, a similar pattern in the levels of IgG antibody responses specific for A/WSN (Figure 40E), 
A/Cal (Figure 40F) or group 1 HA stalk domain (Figure 40G) were observed in young adult male 
mice.  
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HA VLP or HA-Cy VLP (1 µg each) boosted male mice were protected against A/WSN while 
the naïve group did not survive (Figure 41A). When the mice groups were infected with A/Cal 
(Figure 41B), significantly enhanced protection was observed in the immunized mice with 1 µg of 
each VLP (11% body weight loss) compared to the naive group (17% body weight loss). Taken 
together, these results suggest that male BALB/c mice induced comparable immune responses 
and cross-protection after HA VLP or HA-Cy VLP vaccination as observed in female mice. 
 
Figure 40 Comparable levels of serum IgG antibody responses are induced in female 
and male young adult mice after PR8 HA VLP immunization 
BALB/C mice (n= 6/group) of young female (f) and male (m) were immunized with prime-boost doses (1 
µg) of HA VLP or HA-Cy VLP at an interval of 3 weeks. IgG antibody responses in mouse prime (A) and 
boost sera (B-G) were measured by ELISA at 2 weeks after each immunization. IgG (A, B), IgG1 (C), and 
IgG2a (D) antibody responses to A/PR8.  IgG antibodies to A/WSN (E), A/Cal (F) and group 1 stalk domain 




Figure 41 Male young adult mice vaccinated with PR8 HA VLP or PR8 HA-Cy VLP are 
protected against heterologous A/WSN or A/Cal virus challenge  
Body weight changes after challenge with (A) A/WSN (8 LD50, 8.7 EID50) or (B) A/Cal virus (2 LD50, 103.6 
EID50) in young adult male mice (n= 3/group) immunized with 1 µg of HA VLP or HA-Cy VLP. Each individual 
mouse is analyzed. Error bars indicate mean ± SEM. 
4.5 Discussion 
Prior clinical trials in healthy adults reported acceptable safety and immunogenicity 
results of influenza HA VLP vaccines (2009 H1N1, H5N1, H7N9) produced in insect cells, 
comparable to conventional influenza vaccines (Pillet et al., 2019, Lopez-Macias et al., 2011, 
Landry et al., 2010, Fries et al., 2013), supporting VLP as a potential vaccine platform. In this study 
to better understand immune responses to vaccination in elderly, we compared dose-dependent 
immunogenicity and efficacy against homologous and heterologous influenza viruses in young 
adult and aged mouse models. The aged mice required higher doses to induce IgG antibodies for 
homologous viral antigens but displayed low capacity to generate IgG antibodies for 
heterologous viruses and HA stalk proteins, compared to young adult mice. The immunogenicity 
and efficacy of HA VLP were comparable in female and male mice.  To enhance vaccine efficacy 
in aged mice, the adjuvant effects of cytokines (GM-CSF, IL-12) incorporated onto HA VLP (HA-Cy 
VLP) were investigated. Cytokine adjuvant effects of HA-Cy VLP were prominent on inducing T 
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cell responses in young and aged mice, and on lowering lung viral titers in aged mice after 
vaccination and challenge.   
Intramuscular vaccination with HA VLP (A/Cal/09, 10 µg) was previously shown to confer 
protection against homologous A/Cal virus and partial protection against heterologous 
A/WSN/33 in young adult female BALB/c mice (Quan et al., 2010). High dose (10 or 40 µg) of PR8 
HA VLP repetitive intranasal immunization induced protection against homologous (A/PR8/34) 
and heterologous (A/WSN) viruses (Quan et al., 2007). These previous reports are consistent with 
the results from this study demonstrating high IgG antibodies and HAI titers by low dose (1 µg) 
PR8 HA VLP in young adult mice. In contrast, higher doses (3 or 6 µg) of PR8 HA VLP were required 
to induce substantial HAI titers in aged mice, which were still lower than those in young adult 
mice. This result supports the current vaccine strategy that high dose influenza vaccines (4-fold 
higher dose than standard vaccine) are recommended for adults ages 65 and older (Li et al., 
2021). A/WSN/33 is antigenically closer to A/PR8/34 (87.1 % amino acid sequence homology in 
HA1) compared to A/Cal/09 (76.5% amino acid sequence homology), suggesting that antigenic 
distance is correlating with the levels of cross-reactive IgG antibodies. Immunological impairment 
in aged mice was more prominent in generating IgG antibodies for heterologous viral antigens 
(A/WSN, A/Cal) and immune-subdominant HA stalk proteins compared to young adult mice.  This 
is in line with the aging immunosenescence and waning immune system, severely limiting the B 
cell repertoire diversity in the elderly population at greater risk of influenza infection compared 
to young individuals (Nikolich-Zugich, 2018, Reber et al., 2012). Moreover, reduced affinity 
maturation of antibody via somatic hypermutation (SHM) caused by the defects in germinal 
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centers from elderly population has been described (Dunn-Walters et al., 2003, Frasca and 
Blomberg, 2009). 
With a low dose (1 µg) of PR8 HA VLP immunization, young adult mice induced protection 
preventing weight loss against homologous A/PR8/34 virus challenge, while aged mice displayed 
severe weight loss (~18%). For enhanced protection without weight loss, aged mice required a 
higher dose (3 µg) HA VLP which was still not capable of clearing lung viral titers. These results of 
homologous protection appear to be strongly correlated with HAI activity titers in immunized 
mouse sera (Figure 35). The young adult group showed high HAI responses to homologous 
A/PR8/34 virus even with low dose (1 µg) of PR8 HA VLP whereas higher doses (3 µg or 6 µg) 
were required to elicit sufficient HAI titers since 1 µg PR8 HA VLP vaccination in aged mice HAI 
titers induced very low HAI titers. Vaccinated young adult mice with PR8 HA VLP (1 or 3 µg) 
showed 100% protection against A/WSN/33 virus and survival protection against A/Cal/09 virus. 
Aged mice with 1 ug HA VLP were not protected against A/WSN/33 virus and protection of 
lowering lung viral titers by several hundred-folds was observed in aged mice with a higher does 
(6 µg). Aged mice were not protected against A/Cal/09 virus (data not shown). Both young adult 
and aged mice had negative HAI titers to heterologous A/WSN/33 and A/Cal/09 viruses, 
suggesting that heterologous protection was mediated by non-neutralizing immunity. Consistent, 
seroconversion rates post vaccination for elderly were less than 30% while young adults showed 
50-75% seroconversion rates (Crooke et al., 2019). The declined vaccine-induced humoral 
responses are attributed to the reduction of neutralizing and HAI activities of antibodies in elderly 
individuals (Sasaki et al., 2011).  
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Use of GM-CSF as adjuvant such as DNA vaccine and antigen targeting was reported to 
promote antibody avidity maturation (Lai et al., 2007) and cross-priming (Chiodoni et al., 1999, 
Skountzou et al., 2007).  IL-12 activates dendritic cells, macrophages, T lymphocytes and natural 
killer (NK) cells, and cytotoxic CD8 T cell responses (Fallon et al., 2014, Jaffee, 1999, Trinchieri and 
Scott, 1999, Vagliani et al., 1996, Trinchieri, 1994). We wanted to test a hypothesis that 
incorporation of GM-CSF and IL-12 onto PR8 HA VLP (HA-Cy VLP) would overcome the weak 
immune system in an aged mouse model. In young adult mice, the impact of different doses of 
HA-Cy VLP vaccination was not significant on inducing humoral responses such as IgG and HAI 
titers, and on cross-protection against A/Cal virus although the HA-Cy VLP group induced higher 
levels of IgG antibodies for A/WSN and IFN-γ+ CD4 and CD8 T cell responses. PR8 HA VLP 
exhibited sufficient immunogenicity and protection, clearing lung viral replication against A/PR8 
virus and A/WSN virus in young adult mice. In contrast the aged mice with HA-Cy VLP vaccination 
were more effective in preventing weight loss against homologous A/PR8 virus challenge, and in 
lowering lung viral titers after homo (A/PR8) and hetero (A/WSN) virus challenge as well as in 
inducing higher levels of INF-γ+ CD4 and CD8 T cell responses. Nonetheless, there were no 
significant increases in IgG antibodies and HAI titers in the HA-Cy VLP group compared to the HA 
VLP group in aged mice, suggesting that cytokines incorporated onto HA VLP exhibit adjuvant 
effects on enhancing cellular T cell responses. Induction of IFN-γ+ CD4 T cells was critical in lung 
protection and host survival (Green et al., 2013), supporting a possible role of T cell immunity in 
cross-protection. In addition, HA stalk antibodies and cytotoxic CD8 T cells induced by VLP 
vaccination might have contributed to protection against influenza virus (Hemann et al., 2013, 
Jang and Ross, 2021). Particularly, there have been several studies to develop universal influenza 
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vaccines by targeting the conserved HA stalk domains (Nachbagauer et al., 2021, Margine et al., 
2013, Mullarkey et al., 2016). However, HA stalk specific antibodies are rarely induced by 
inactivated influenza virus vaccination (Krammer and Palese, 2013). We found that HA VLP 
vaccination was effective in inducing HA stalk specific IgG antibodies in young adult mice but not 
in aged mice. Thus, it is also possible that HA stalk specific IgG antibodies induced in young adult 
mice might have contributed to more effective cross-protection in your adult mice than aged 
mice. Taken altogether, a strategy of cytokine-adjuvanted HA VLP vaccination might provide a 
potential vaccine platform for elderly population. 
5 DISCUSSION AND FUTURE DIRECTION 
5.1 Enhanced cross-protection by a single intranasal dose of recombinant influenza virus 
vaccine inducing M2e and HA immunity 
Highly conserved M2e is a promising target as universal influenza vaccine and M2e-based 
protective immunity has been reported in numerous previous studies (Lee et al., 2015a, Deng et 
al., 2015). However, M2e is a poor immunogen and M2e immunity standalone provides relatively 
weak broad cross-protection due to non-neutralizing immune mechanisms (Lee et al., 2016b). To 
enhance the immunogenicity of M2e, multiple strategies have been introduced, which include 
M2e presenting VLP (Kim et al., 2013b, Kim et al., 2018), toll-like receptor (TLR) (Mastalerz-Migas 
et al., 2015b, Miller et al., 2020), gold nanoparticles, liposomes and immune stimulating 
complexes including cholera toxin subunit (Calzas and Chevalier, 2019). Clinical trials for M2e-
based vaccine safety and efficacy were carried out. An M2e-flagellin fusion vaccine was 
immunogenic in 96% vaccine recipients in phase I trials after low prime-boost dose but showed 
adverse effects with high doses that might be due to the toxicity of the flagellin adjuvant (Lee et 
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al., 2014b, Turley et al., 2011, Taylor et al., 2011). Another clinical trial utilized ACAM-FLU-A (M2e 
epitopes fused to hepatitis B core protein) and reported the induction of M2e-specific antibodies 
in a phase I clinical trial (ClinicalTrials.gov Identifier No. NCT00819013) (reviewed in (Zheng et al., 
2014)). The major objective of my dissertation projects was to test whether extra M2e immunity 
in addition to homologous virus neutralizing antibodies would enhance broad cross-protection 
in a mouse model after single dose intranasal immunization with recombinant influenza virus 
vaccines expressing chimeric 4xM2e-HA molecules.  
Previous studies investigated M2e-induced protective immunity and secondary long term 
immune impacts using a VLP vaccine platform (M2e-VLP) in comparison with HA-based vaccines 
(Lee et al., 2016b, Schotsaert et al., 2013, Schotsaert et al., 2016). M2e vaccine-induced immunity 
provides infection-permissive protection against sublethal doses of heterosubtypic influenza 
viruses whereas HA-based trimeric soluble HA protein (Schotsaert et al., 2016), whole inactive 
virus (Schotsaert et al., 2013), and split vaccines (Lee et al., 2016b) were highly effective in 
inducing strain-specific homologous protection but not antigenically different influenza viruses. 
These studies clearly demonstrated the immunological benefits of M2e-based vaccines 
conferring survival protection and often preventing severe morbidity against heterologous 
viruses compared to HA-based seasonal vaccination ineffective in inducing cross-protection.  
M2e-based immunity was reported to induce cross-reactive CD8+ T cells contributing to cross-
protection (Lee et al., 2016b). The M2e immune mice that were protected against primary lethal 
challenge infections developed strong long-term immunity against heterosubtypic viruses during 
secondary infections (Lee et al., 2016b, Schotsaert et al., 2013, Schotsaert et al., 2016). In 
contrast, the HA-based vaccinated mice that were completely protected against homologous 
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virus were highly susceptible to secondary heterosubtypic virus infections, mimicking pandemics 
(Lee et al., 2016b, Schotsaert et al., 2013, Schotsaert et al., 2016). As an alternative vaccination 
strategy, VLP expressing five tandem repeat M2e (M2e5x VLP) showed prominently enhanced 
cross-protection against a lethal dose of heterosubtypic influenza virus when it is supplemented 
to licensed split influenza vaccine compared to split vaccine only (Kim et al., 2014). Split vaccine 
induced strain specific but highly effective homologous protection while M2e4x VLP provided 
cross-protection against different subtypes of influenza viruses, despite weak protection 
accompanied with body weight loss in a mouse model (Lee et al., 2016b). Therefore, M2e 
immunity has limitation as a sole vaccine antigen although M2e-based vaccination confers 
relatively weak cross-protection. 
Moreover, homologous serum hemagglutination inhibition (HAI) titers and neutralizing 
antibodies induced by HA-based vaccines against homologous influenza virus should be 
considered in developing universal vaccines and effective vaccination strategies translatable to 
humans. Vaccination strategies inducing both M2e immunity and neutralizing HAI antibodies 
provided scientific rationales for my projects 1 and 2 of testing recombinant 4xM2e-HA influenza 
virus vaccines.  
In chapter 1, I have investigated the enhanced efficacy of cross-protection by single 
intranasal immunization with recombinant live influenza virus vaccine that expresses chimeric 
HA with an insertion of four tandem repeats of M2e domains in its N-terminus (4xM2e-HA). 
Sufficient M2e specific antibodies were induced in BALB/c mice even with an intranasal single 
dose of recombinant H3N2 subtype influenza virus that carries 4xM2e-HA (rgH3N2 4xM2e). The 
impact of M2e protective immunity on inducing enhanced cross-protection was prominent after 
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challenge with different subtypes of influenza viruses including H1N1, H3N2, H5N1, H7N9 and 
H9N2. These results are consistent with other animal studies (mice or ferrets) describing that 
M2e can induce broad permissive cross-protection against different subtypes of influenza viruses 
(Tao et al., 2017, Ingrole et al., 2021, Deng et al., 2015, Mezhenskaya et al., 2019).  
5.2 Improvement of cross-protection by inducing both HA and M2e immunities with 
heterologous prime-boost immunization with recombinant influenza virus vaccines 
As seasonal influenza vaccinations are annually recommended in 6 months ages and older 
individuals, the effects of repeated vaccination need to be investigated further. A study 
performed in 2014 (McLean et al., 2014) described a reduced vaccine effectiveness in the group 
where had vaccinated over the prior five years compared to those individuals not receiving 
vaccine previously or those who received only the previous year’s vaccine. This result implies that 
vaccination history might affect vaccine effectiveness. Similar observations were reported in 
another study (Smith et al., 1999) and this phenomenon was explained as “an antigenic distant 
theory”. When the vaccine components have small antigenic differences between current and 
last season’s vaccines, current seasonal vaccination may augment and stimulate preexisting 
memory B cells induced by previous season vaccination or infection. As a result, the immune 
response to current vaccine antigens can be interfered (antibody interference) (Murray, 2015). 
Consistent with these previous studies, in the chapter 2 of my project 2, I found that enhanced 
cross-protection was induced by heterologous prime-boost immunization with recombinant live 
influenza H1N1 and H3N2 subtype viruses expressing 4xM2e in their chimeric HA molecules. 
Enhanced cross-protection by heterologous prime-boost with recombinant influenza virus 
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vaccines was found to be correlated with increased cross-protective IgG antibodies specific for 
M2e and HA stalk domains compared to homologous prime-boost immunization in C57BL/6 mice.  
In both project 1 and project 2, M2e epitopes were conveyed in live attenuated influenza 
virus (LAIV) platform to overcome the drawbacks of M2e alone weak immunogenicity and 
efficacy. LAIV mimicking natural infection is one of primary influenza vaccine types and believed 
to have a greater potential to induce cross-protective humoral and cellular immune responses in 
animals and in young children (Ambrose et al., 2011, Carter and Curran, 2011). I also observed 
cross-reactive IgG antibodies after rgH3N2 (4xM2e) or attPR8 (4xM2e) live influenza virus 
immunization. The cross-reactive antibodies have been reported to contribute to protection 
against heterologous virus challenges in animal models (Dong et al., 2018, Nachbagauer et al., 
2017a) and in clinical investigations(Mandelboim et al., 2014, Chen et al., 2018).  
Although vaccination is particularly important for vulnerable older adults, the influenza 
vaccine efficacy is significantly less in the elderly due to immunosenescence than in younger 
adults. In project 2, C57BL/6 mice at 1-year-old age received heterosubtypic prime-boost 
immunization with live attenuated influenza vaccines (LAIV) including attPR8 4xM2e and H3N2 
4xM2e showed partial protection against A/Viet rgH5N1 virus infection and displayed reduced 
IgG antibody responses to vaccine antigens compared to young adult mice. Since LAIV is still a 
live virus, it is recommended only for healthy people 2-49 years of age (CDC, 2021c). Also, LAIV 
has some limitations with variable vaccine efficacy in individuals who already have been exposed 
to influenza virus partially due to their preexisting antibodies (Lopez and Legge, 2020). Clinical 
study has investigated the effectiveness of the LAIV during 2014-2015 influenza season (Matrajt 
et al., 2020) that is wide discrepancies in vaccine effectiveness (VE) between studies. The 
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research group explained the causes of different VE using mathematical models and suggested 
antigenic distances (AD) between the vaccina strain, pre-existing immunity, and the challenge 
strains as the main factors. In brief, VE would be low if the antigenic distances are small between 
the HA of vaccine strains and prior HA strains responsible for pre-existing immunity. This is 
consistent with the Original Antigenic Sin (OAS) theory (Zhang et al., 2019, Adalja and Henderson, 
2010). Replication of LAIV in the upper respiratory tracts for inducing immune response would 
be limited by pre-existing immunity if the vaccine strain and pre-immunity are antigenically 
similar. Generally, VE of LAIV is higher in younger population who is relatively naïve individuals 
and in naive animal models. The efficacy of LAIV have shown discrepancies between in animal 
models and clinical studies. LAIV elicits superior efficacy compared to inactivated influenza 
vaccine (IIV) in animal model while clinical reports showed less efficacy in LAIV (Chung et al., 
2019, Chen et al., 2010, Roy et al., 2020b, Roy et al., 2020a). It is explained by the impact of pre-
existing immunity that reduce LAIV efficacy (Roy et al., 2020b). Therefore, LAIV vaccination need 
to be improved to induce enhanced effectiveness of vaccines. A ferret study (Nachbagauer et al., 
2017b) reported heterologous vaccination strategy using chimeric HA vaccines, demonstrating 
higher protective immunity against pandemic H1N1 virus challenge from LAIV-spilt sequential 
immunizations compared to IIV-IIV immunization, which was not replicated in phase 1 clinical 
studies using similar vaccination strategies (Bernstein et al., 2020).  
Intramuscular injection of inactivated vaccine is commonly used for influenza seasonal 
vaccination. In project 1, intranasal inoculation of single dose live H3N2 4xM2e induced a 
significant level of M2e specific IgG antibodies that contributed to enhanced cross-protection in 
BALB/c mice. However, inactivated H3N2 4xM2e failed to induce detectable M2e specific IgG 
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antibody responses after single dose intramuscular immunization and did not provide improved 
cross-protection even after second boost compared to the control inactivated virus with wild 
type HA (data not shown). No improved cross-protection might be due to the low levels of IgG 
antibodies for M2e and the induction of other non-M2e immunity such as conserved HA stalk 
and NA. A strategy of recombinant influenza viruses expressing conserved M2e epitopes at the 
N-terminus of HA would not be effective in inactivated vaccine platforms. 
In contrast, previous studies reported alternative strategies of recombinant influenza 
viruses where the foreign epitopes (M2e, conserved NA or neutralizing epitopes of respiratory 
syncytial virus fusion protein) inserted in the immunodominant HA head domain of influenza 
viruses that induced epitope specific antibodies in inactivated vaccine platforms and conferred 
improved protection against challenge with antigenically different viruses  (Kim et al., 2020, Lee 
et al., 2016a). Locations of foreign epitopes inserted into the chimeric HA might be attributed to 
inducing immune responses to the inserted region of HA in either LAIV or inactivated vaccine 
platforms. Structurally, the HA head domain is highly immunogenic whereas the N-terminus is 
more flexible that could be conjugated as large as 246 amino acids with retaining the HA 
functionality. However, the HA head domain only allows less than 18 amino acids to maintain the 
HA functionality. Therefore, different strategies should be considered in engineering 
recombinant influenza viruses to improve the vaccine efficacy, depending on the employment of 
vaccine platforms.  
For future studies to induce cross-protective immune responses, another conserved 
domain, supplementation of HA stem immunity can be considered. While HA head domain is 
highly immunogenic but hypervariable, HA stem domain is immune subdominant but conserved 
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within the same HA group (Yassine et al., 2018, Ekiert et al., 2011). The HA stem possesses 
neutralizing epitopes that allow to induce cross-protective IgG antibodies against different 
subtypes of influenza virus (Thrane et al., 2020). In a previous study using nanotechnology (Deng 
et al., 2018) have described vaccine efficacy of double-layered protein nanoparticles 
incorporated with both HA stalk domains (from A/PR8 H1 or A/Aichi H3) and M2e (Uni4C13) in 
BALB/c mice. Enhanced cross-protection mainly induced by ADCC (antibody-dependent cellular 
cytotoxicity) and ADCP (antibody-dependent cellular phagocytosis) and similar findings were 
described using chimeric conjugated protein vaccine of thermostable H1 HA stem and M2e 
repeat (M2e-H1stem) (Jeeva et al., in preparation). In addition, improved cross-protective 
vaccine efficacy was observed in young and aged BALB/c mice immunized with VLPs displaying 
multi- consensus epitopes of NA subtypes and 5xM2e (Kim et al., under review). 
5.3 Influenza vaccination for the elderly 
In chapter 3, virus-like particle (VLP) was used as vaccine platform to induce protective 
immune responses in old aged (18-month-old) BALB/c mice. The safety and immunogenic 
features of VLP represent attractive applicability particularly for immunocompromised or elderly 
people. Currently, multiple VLP-based vaccines are available for clinical trials or commercial uses. 
VLP-based vaccines for human papillomavirus, hepatitis B virus, and malaria have been approved 
by U.S. food and drug administration (FDA). And other VLP-based vaccines are under clinical trials 
against variety of viruses including seasonal influenza (phase 3, trial No.: NCT03301051, plant-
derived quadrivalent VLP and NCT04120194, protein nanoparticle), pandemic influenza (phase 
2), RSV (phase 3), human immunodeficiency virus, Ebola, and COVID-19 (phase 1) as reviewed in 
(Nooraei et al., 2021).  From the project 3 studies to investigate protective immune responses to 
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HA VLP vaccination in aged mice, I found that aged mice required higher doses of PR8 HA VLP 
vaccine than young adult mice to provide protective responses to homologous and heterologous 
viruses. This is consistent with a current influenza vaccine strategy that older people ≥ 65 years 
are suggested to receive high-dose vaccine such as Fluzone® High-Dose Quadrivalent licensed 
inactivated influenza vaccine that contains influenza A and B strains (60 µg of each 
hemagglutinin). Adjuvanted inactivated influenza vaccine, FLUAD Quadrivalent is approved only 
for 65 years and older in U.S. in November 2015 at 18 years later of the approval in Italy (CDC, 
2021a). This vaccine contains MF59 which is an oil-in-water emulsion of squalene oil. The 
mechanism of this adjuvant is not fully understood but it triggers immunostimulation and 
significantly enhance the immunogenicity (Li et al., 2021). However, there is still some gaps to be 
improved due to the shortcomings during the vaccine preparation that utilizes eggs. Egg 
adaptation mutation might affect the vaccine effectiveness and egg proteins in the vaccine 
ingredients can cause allergic responses. HA VLP contains lipid bilayer membranes as in the 
enveloped influenza viruses and thus was reported to be easily amenable for incorporating GPI-
anchored cytokine adjuvants (Patel et al., 2015b, Patel et al., 2015a). Therefore, we selected a 
VLP vaccine platform and tested the impacts of cytokine molecular adjuvants (GM-CSF and IL-12) 
incorporated onto PR8 HA VLP aged (PR8 HA-Cy VLP) in BALB/c mice. PR8 HA-Cy VLP was able to 
enhance protective efficacy by reducing lung virus titers in aged mice. These results from the 
project 3 studies on HA VLP with cytokine adjuvants provide new insights into developing 
effective vaccination in aged population.  
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5.4 A new platform of mRNA-based next generation influenza vaccines  
As a future direction for developing effective vaccination strategies, recently, the success 
of mRNA vaccines against COVID-19 has shown the potential as a next generation influenza 
vaccine platform. One of advantages of mRNA vaccine over current vaccines is that it can be 
produced rapidly (6-8 weeks) compared to current influenza vaccines which takes 6 to 9 months. 
This allows rapid update of genome sequence for effective vaccine formulations (Meurens, 
2020). Also, its cost-effective synthetic format provide safety which does not require 
complications of cell- or egg-based production. The mRNA vaccine is an inherently unstable 
molecule and easily degraded by nucleases (Wadhwa et al., 2020). Lipid nanoparticles (LNPs) 
provide a promising vehicle that enables delivery of nucleic acids of mRNA into cells effectively 
by receptor-mediated endocytosis as it is worked well and proven for COIVD-19 mRNA vaccines 
(Hou et al., 2021, Schoenmaker et al., 2021). Numerous relevant preclinical data have been 
reported. In 2012, Kramps’ group (Petsch et al., 2012) firstly demonstrated protective efficacy of 
mRNA vaccine against infectious disease (influenza) using animal models. In addition, multiple 
clinical trials have been initiated for influenza mRNA vaccine development. Currently, influenza 
HA-based mRNA vaccines (phase 1 or 2, Moderna, mRNA-1010, Sanofi/Translate Bio, MRT-5400, 
MRT-5401, and Pfizer, PF-07252220) are in clinical trials (ClinicalTrials.gov) and the clinical 
findings of SARS-CoV-2 mRNA vaccine that induced protective immune response in the elderly 
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